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ABSTRACT 
The purpose of this thesis was to study the human complement com-
ponents, C6 and C7, in Newfoundland and to pursue the genetics of these 
proteins within the limits of the material obtained and the time allow-
ed. 
Approximately 2400 sera from three Newfoundland populations were 
allotyped by the method of isoelectric fOCUSing in polyacrylamide gel 
followed by specific hemolytic overlay. The frequencies of the cOUDllOn 
alleles were calculated for two of these populations. The West Coast 
community had rrequencies of C6*a (0 . 6321) and C6*B (0 . 3670) and the 
Newfoundland families plus random individuals in a group had C6*A 
(0.6947) and C6*B (0 . 2980) . These frequencies are similar to those 
found in other populations. The C6 alleles observed in the three po-
pulations were inherited in a manner consistant with a single autoso-
mal locus and there was no evidence to suggest selection against the 
inheritance of the rare alleles . Examination for linkage of C6 with 
HLA reiterated the negative results of previous studies. An attempt 
to link the C6 and SOD (superoxide dismutase) loci in a West Coast 
family having a rare SOD variant was made but the data were uninforma-
tive. 
The homozygous C7*1 pattern was by far the most commonly observed, 
occurring in more than 99 % of the samples allotyped. The novel obser-
vation and investigation of an artifact associated with prolonged serum 
storage of the C7*1 protein such that it is modified and mimics the mi-
gration of the C7*3 protein during isoelectric fOCUSing is described. 
Genuine C7*3 alleles were also observed, two in heterozygote form. 
C7 3-1 . and one which was due to either C7*3 homozygosity or C7 3- 0. 
Data suggesting the C7*2 allele is of Chinese origin are presented . 
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ADDENDUM 
Since the final writing of this thesis. nine unrelated local Chinese 
people have been bled and their serum typed for C7. Of the nine. three 
were heterozygous for C7"'2. This supports the suggestion that this al-
lele is of Chinese origin and appears with a frequency of approximately 
17%. Further studies are currently in progress to accumulate family 
data for linkage efforts. 
SECONO AOOENOUM 
Following evaluation of this thesis it has been pointed out that the 
term "a llele" has been used here. as it sometimes is in published literature 
on C6 & C7. in an imprecise manner. The DNA sequence coding for a polymorphic 
polypeptide is, strictly speaking the "allele" . whilst the polymorphic poly-
peptide or protein should be referred to as the "gene product". The thesis 
should be read with this reservation in mind. 
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CHAPTER I INTRODUCTION 
In this chapter, the review of the pertinent literature is divided 
into three parts, each becoming more detailed than the last. An over-
vie'" of the structure and function of the complement system is followed 
by a review of the genetic discoveries and ideas about the system. Fi-
nally, a detailed review of the literature on the genetics of the sixth 
and seventh complement components, the subject of the present thesis, is 
presented. 
OVERVIEW OF THE COMPLEMENT SYSTEM, STRUCTIJRE AND FUNCTION 
For this overvie"" the follOwing revie'" articles have been used to 
provide much of the material for the classical pathway: 
Huller-Eberhard , H.J., 1968 
Muller- Eberhard , H.J . , 1970-71 
Muller-Eberhard, H. J . , 1974 
Frank, M.M . , 1975 
and the following for the alternative pathway: 
Osler, A. G. and A. L. Sandberg, 1973 
Gotz.e, O. and H.J. Huller-Eberhard, 1976 
Huller-Eberhard, H.J. and R.D . Schreiber, 1980 
Feardon, D.T. and K.F. Austen, 1980. 
When first identified, complement was though to be a single serum 
factor that acted in conjunction with antibody to cause cell lysis. Its 
first investigator, Pfeiffer, in 1894, studied the bacteriolytic proper-
ty of serum from immuniz.ed guinea pigs. Heating of the serum at 56°C 
for one half hour resulted in loss of the bacteriolytic activity. How-
ever, upon addition of fresh serum from non-immunized guinea pigs, the 
sensitized cells could be lyzed. Four years later. Bordet idl!ntified 
the requirement for this same thermolabile serum factor for immune hemo-
lysis . Since that time , complement has been shown to be a multifactor 
syatem made up of at least twenty discrete proteins that have been iso-
lated and each assigned various activities. 
-2-
With properties such as chemotaxis, opsonization, immune adherence. 
anaphylatoxin activation, promotion of blood coagulation and virus neu-
tralization, as well as immune hemolysis, the complement system 1s com-
plex and intricate . It can, however , be looked at as a Simple cascade 
of the components acting upon each other in a precise sequence. The 
multistep system l imits the amount of host cell destruction in the vi-
cinity of the recognized antigen by two means. Firstly, the components 
exist in serum and the body fluids as inactive proteins and secondly . 
when activated by specific biochemical steps , the enzymatic half-life 
of the proteins 1s very short . 
When describing the mode of action by which the complement system 
works, a three unit model has been adopted (Go'tze, 0 , and H.J , M'uller-
Eberhard , 1970) : a recognition unit comprised of subcomponents Clq , 
Cir and CIs; an activation unit of C4, C2 and C3; and finally, the mem-
brane attack unit of C5 , C6 , C7, C8 and C9 , Not one of the proteins is 
dispensible and the cascade must proceed in a precise sequence for ef-
ficient cytolysis. Slow lysis will occur without the addition of C9 
(Stolfi, 1968) b u t upon its addition the rate is g r eat l y incr eased 
(Haxby and Kolb , 1972) . 
The Recognition Unit 
Complement 1s activated by antibodies of the IgM and mos t 19G clas-
ses (strongly by Y 1 and Y 2 ' weakly by Y 3) and not activated by the immu-
noglobulins 19A, 19D , 19E or Y 4 (lshizaka et a1. 1966; l shizaka et al. 
, 
1967; Augener et a1. 197 1). 
The first component, Cl, exists 1n serum as a complex of subunits 
CIq, Clr and Cis in the r atio of 1:2:4 respectively (Naff et a1. 1964). 
The macromolecule is stabilized by calcium ions (Lepow et al. 1963), 
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Recognition of the antibody-antigen complexes Is mediated by the globu-
lar tulip-like head structures of Clq. Clq has six of these heads, 
each on its own thin tendril attached to the central unit. Clq binds 
to the Fe portion of the illDJlunoglobulin (Kehoe and Fougereau. 1969) 
and it Is thought that the action of the binding causes a change in 
the conformation of the central unit which results in a modification 
of Cir. revealing the elr enzymatic site which activates CIs. 
Esterolytlc activity resides in the Cis subunit and will enzyma-
tleally cleave the unactivated precusors of C3- convertase, C4 and C2 
(Naff et 81. 1964). 
The Activation Unit 
C4 is enzymatically fragmented into a small molecular weight unit. 
C4a. which is released into free solution. The remaining activated lar-
ger fragment, C4b, attaches itself to the membrane around the site of 
the immunoglobulln-CI complex. Activated Cl (CI) fragments hundreds 
of C4 molecules. A protecting inhibitor, CI - INH, binds to the cl"ii 
site ~nd thus limits the consUlllption of C4 (Levy and Lepow, 1959). Al-
so, the binding of the C4b fragment to the antigen membrane is ineffi-
cient, only approximately 10% of all the fragmented C4b doing so. The 
free C4b has a very short half-life, soon becoming C4b i , and this again 
decreases the amount of host cell damage. 
C4b bound to the membrane exhibits a binding site for C2 which is 
also activated by the esterolytic action of cl"ii. C2 is fragmented as 
was C4, into C2a and C2b. The larger, C2a, binds to C4b to f6rtn C4b2a. 
known as C3-convertase (Hayer and Miller, 1965). 
The C3- convertase activity resides in the C2a subunit and enzyma-
tically activates C3 (Cooper, 1971). As previously. activation requires 
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the fragmentation of the component Into small and large molecular weight 
subunits, C3a and C3b respectively. This step 1s of great importance 
in that the bound C4b2a converts thousands of C3 molecules into its two 
fragments. there is a focal distribution about the C4b2a site as C3b 
binds to the membrane and C3a is released into the fluid phase (Muller-
Eberhard et a1. 1966). Only the C3b closest to the site of the bound 
C4b2a wl11 form C4b2a3b, necessary for the formation of the membrane at-
tack unit. 
The Membrane Attack Unit 
Activated, membrane bound C4b2a3h cleaves the next complement pro-
tein, CSt into CSa and C5b. The larger molecular weight fragment, C5b, 
binds to the membrane and upon dOing so, reveals a binding site for C6. 
There is thought to be no fragmentation of the C6 molecule, nor is there 
of C7 which binds to the activated CSb6 complex to form CSb67. It may 
be that binding of C7 to CSb6 reveals a hydrophobic site which allows 
association between the complex and the membrane lipids (Polley et a1. 
1971). The discovery of tributyrinase activity attributable to C7 may 
include this component as an active participant in membrane interaction, 
possibly in the capacity of a lipase (De1.age et a1. 1973). 
Binding of C8 to CSb67 results in slow hemolysIs which is rapidly 
increased upon addition of C9. There is disagreement on the number of 
C9 molecules required for effective lysis, it being either a Single mo-
lecule (Rouunel and Ma~er, 1973; Kitamura and Inai, 1974) or up to six 
(Kolb and Haxby, 1972a; Kolb et a1. 1972b). 
Recently, the hypothesis of the five late components (CS, C6, C7, 
C8 and C9) binding to form a donut-shaped unit which, when inserted in-
to the bilipid membrane layer, would allow diffusion and therefore, ly-
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sls, has been challenged. Nascent CSb-9 complexes have been shown to 
aggregate spontaneously (Podack et 81. 1978; Podack et 81. 1980) snd 
analysis of solute diffusion across the CSb- 9 membr ane lesion now sug-
gests that the pore size is heterogenous and must result from aggrega-
tlon of the bound C5b-9 complexes into multimeric units (Sims and Lauf. 
1980) . 
The Alternative Complement Pathway 
The complement system can also be activated by an alternative path-
way or Properdin pathway . The early components CI, C4 and C2 are by-
passed by Properdin. Factor D and Factor B. 
Credit for the discovery of the Properdin system goes to Pillemer 
and associates, who first recognized that complement activities, spec i-
fie ally bactericidal, virus-neutralizing and hemolytic, could be initi-
ated without the presence of iDDllune aggregates, in conditions that in-
hibit Cl complex formation or in serum deficient in anyone of the ini-
tial components (Pillemer et a1. 1954). 
The Properdin pathway is initiated by polysaccharides, endotoxins, 
cell walls and zymosan (Pillemer, 1956: Pillemer et al. 1955), requires 
magnesium ions (Pillemer et 81. 1954) and consumes what was once known 
as C'3 (Pillemer et a1. '1953: Pillemer et a1. 1956), now known as C3, 
C5, C6, C7, CS, and C9 (Klein and Wellensiek, 1965; Wellensiek and Klein, 
1965: Linscott and Nishioka , 1963: Nilsson and Muller - Eberhard, 1965). 
Early investigation isolated a Factor A necessary in the Properdin sys-
, 
tem but this was later identified as C3b (MInIer-Eberhard and GO'tze, 
1972). The Properdin pathway is thus non-specific in that specific an-
tibody is not required fo r its activation. Presence of immune aggregates 
nevertheless may enhance the activation . 
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Small amounts of C3b are continuously produced by the slow inter-
action of C3, Factor B, Factor D and Properdin. The C3b molecules at-
tach to cell surfaces (Law and Levine, 1977) and in the presence of mag-
neslum ions. Factor B binds to the C3b. Factor 0 then cleaves the bound 
B into two fragments, Ba and Bb, the fragment which cleaves C3. The C3 
cleaving ability of Bb is stabilized by the binding of Properdin to the 
C3b subunit. 
The formation of BbC3b is controlled by SlH which inhibits by ac-
tively blocking the binding of B, by dissociating the B or Bb bound to 
the C3b and by increasing C3b susceptibility to cleavage by C3-inacti-
vat or. The outcome of the competition between SIH and Factor B 1s de-
pendent upon \olhether the C3b subunit has attached to an activator. C3b 
on the surface of a non-activator has a 100 fold greater affinity for 
SlH than for Factor B. However, when bound to an activator surface , 
the uptake of B is favored (Feardon and Austen, 1977a; Feardon and Aust-
en, 1977b). The C3- convertase activity provides, by cleavage of C3, 
more C3b for the formation of BbC3b, (C3-convertase). and forms a posi-
tive feedback loop . It is at this stage that C3 inactivator exhibits 
its property of binding and cleaving C3b into two fragments, C3c and 
C3d. thus stopping the overconsumption of C3 (Ruddy and Austen, 1971). 
C3 inactivator also inactivates. C4b, cleaving it into its inactive 
forms, C4c and C4d (Cooper, 1975). 
The C3b generated by the alternative C3-convertase BbC3b then ac-
. 
tivates C5 and the late components a r e activated and function in the 
same fashion as in the classical cascade. The convergence of the two 
pathways is shown in Figure I which expresses clearly the importance 
of C3 in both. 
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Classical 
I 
Cf b678 
C9~ 
16789 
LYSIS 
Alternat.ive 
B, D, P (fluiil phase) 
\..;' C3b, B, ::.:2) 
approp r iate 
surface 
Figure!. Convergence of the classical and alternative pathways . 
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Mediation of Complement Activities 
Development of techniques that allow separation and purification 
of the specific components allowed identification of the specific pro-
teins which mediate the different complement activities. 
y'l.!.u~ ,!!.e.!!t.!:.a.!.l!.s!.i,2.n: The host's ability to protect against vi-
ral infection is mediated partly through the action of antibody and 
complement. Recognition of the introduced virus as a foreign body re-
sults in spec1fic antibody production against this particular antigen. 
Sensitized virus. that Is virus which has antibody now bound to its cap-
sid coat. forms the necessary antigen-antibody complex for activation 
of the classical pathway . When employing C4-deflcient ser um, sensitized 
Herpes Simplex Virus is not neutralized. Therefore , it can be con-
eluded that C4 is necessary for the viral neutralizing activity of 
complement (Daniels et a1. 1970). Addition of purified complement 
components reveal the enhancing effect of C2 and C3 if the C4 concen-
tration is low. If the C4 concentration is high , the presence of C2 
and C3 does not show enhancement of virus neutralization . It is pro-
posed that the C4b molecules bind to the viral surface and "pile up", 
reducing the ability of the virus to bind to receptors on the cell mem-
branes. through steric hind~ance . 
!~u.!le_a.!!h~r~n.£.e_a!!.d_0E.s~n.!.z~t.!.o!!. : C3-converuse. whether formed 
through the classical or alternative pathway cascade , cleaves thousands 
of C3 molecules into the t wo fragments. C3a and C3b. The larger. C3b. 
binds to the cell membrane and only those closest to the C3- cbnvertase 
will be directly active in illDllUne hemolysis. The other C3b molecules 
deposited on the cell membrane increase immune adherence and act as 
opsonizing factors. greatly increaSing the cell's susceptibility to 
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phagocytosis (Lepow et 81. 1970). Opsonization Is also thought due to 
the C4 of the C14 complex (Cooper, 1969). 
~'!'p'!!'y.!.a.!.o~l.!!. .!.c.!.i~i!y: Cleavage of components C3 and CS yields 
twO small molecular wei,ght fragments, C3a and CSa respectively, which 
by means of immunofluorescence can be shown to bind to receptors on 
mast cell membranes. The ensuing degranulation of the mast cell re-
leases histamine and other agents which increase vascular permeability 
and constriction of smooth muscle (Dias da Silva et al . 1967 ; Lepow et 
a1. 1970). Human C3a and CSa are stronger anaphylatoxins than their 
guinea pig counterparts. 
The anaphylatoxin activity of CSa and C3a is dependent upon an 1n-
tact carboxy-terminal arginine. Cleavage of this residue by an enzyme 
having carboxypeptidase activity results in loss of the activity. 
There is a natural anaphylatoxin inactivator in human serum which in-
hibits in vivo generation of anaphylatoxic activity. The anaphylatoxins 
are thus only able to exert their effects at the site of activation ; 
and the potentially immense amount of imflammation caused by the anaphy-
latoxic activity present in human serum is prevented (Bokisch and Muller-
Eberhard, 1970). 
Purified human C2 treated with the enzyme trypsin is cleaved into 
two peptides, one of which exhibits physicochemical and biological pro-
perties similar to a peptide generated by the interaction of cT;, C4 
and C2, which increases vascular permeability (Klemperer et a1. 1969). 
Recently, C4a was identified as an anaphylatoxin of lesser activity 
than C5a or C3a and similarly is inactivated upon removal of its carbo-
xy-terminal arginine (Gorski et al . 1979). 
Chemotaxis : Initial studies on the chemotactic activities of se-
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rum indicated the role of complement components because heated serum 
or serum with the addition of EDTA were found to have no chemotactic 
activity. Both these se r um states render the initial components in-
active . Heating inactivates by disturbing the J;Dolecular configuration 
of C2. C4 and Factor B. and addition of EDTA chelates the divalent 
ions necessary in the initial stages of the two pathways; calcium fo r 
stabilization of the Cl complex and magnesium which allows binding of 
Factor B t o C3b . 
Chemotactic activity for neut r ophil and eosinophil leukocytes is 
present in purified CSb67 but not in CSb6 . suggesting C7 is an essen-
tial part of the complex. However. upon binding of CSb67 to erythro-
cyte membranes or other hydrophilic surfaces. ita chemotactic effect 
is lost. Therefore. it is not a primary factor in the chemotactic 
property of complement (Lachmann et al . 1970) . 
Further experimentation determined the majority of chemotactic 
activity in guinea pig ser um was a product of CS cleavage (Snyderman 
et a1. 1969) . Sucrose - density gradient centrifugation and Sephadex 
c hromatography made possible isolation of two peaks having chemotac-
tic activity for eosinophils and neutrophils (Kay, 1970) . One peak 
was identified as CSa (Kay et a1. 1971) . 
CSa is also a chemotactin for mononuclear leukocytes, important 
in wound healing in their function of phagocytosing degenerating po-
lymorphonuclear leukocytes and tissue debris (Snyderman et a 1. 1971) . 
Use of anti- CS selectivel y inhibits chemotactic activit y. whHe clea-
vage of CS by t rypsin artificially generates this activity (Snyderman 
et a1. 1972). 
Al though cleavage o f C3 by trypsin does not result in chemotactic 
-11-
activity (Snyderman et a1. 1971), use of the enzyme plasmin generates 
a peptide thought to be C3a having the activity (Ward, 1967). 
!r£m£t.!.oE. £.f_b.!o£.d_c£a£ula!.i£n: Rabbits, identified as being de-
ficient in component C6 (Rother et a1. 1969), are noted as having pro-
longed clotting time and abnormal clot retraction. Both condition are 
corrected by the addition of purified C6 (Zimmerman et a1. 1971) . Al-
though aimilar studies in humans deficient in C6 reveal no such abnor-
malities (Lim et a1. 1976; Heusinkveld et a1. 1974), it has been sug-
gested by Zimmerman et a1. (1971) that C6 and therefore complement acts 
in some unknown manner in normal blood coagulation. 
COMPLEMENT GENETICS 
Similarities Between Complement Components 
A number of the complement components exhibit simil a rities both 
phYSicochemically and biologically and it is thought that the common 
proteins may have arisen from successive gene duplication. These simi-
larities are shown in Table I, where the number of peptide chains and 
molecular weight for each component is listed. 
!u,£c£m.2.oE.eE.t,! fIE. ,!.n£ fl,!: Both subcomponents are Single poly-
peptide chains and having similar amino acid composition, share simi-
lar molecular weights (Sim and Porter, 1976) . 
.f0'!!p£.n~n.!.s_C! ~n.!! Ia.£t£.r_B: Similar in molecular weight; C2, 
102,000 and Factor B, 100,000, share an analogous function in that 
each forms C3-convertase and possess the enzymati c site for C3 conver-
sion. Single , heat-labile polypeptide chains with similar amino acid 
composition (Kerr and Porter, 1978) , they also show similarities in 
their susceptibility t o proteolysis and there is a limited degree of 
sequence homology at the sites of cleavage (Kerr, 1979). Also, being 
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Table I. Proteins of the complement system. 
Components Number of Molecular Approxima te 
Classical Peptide Weight Serum Concentra-
Components Chains tion (~g/ml) 
Clq 18 410.000 180 
Clr I 83.000 50 
CI, 83.000 50 
C4 206.000 400 
C2 102,000 IS 
C3 180 , 000 1200 
C5 180,000 80 
C6 124 , 801 75 
C7 120 , 806 55 
C8 163,000 80 
C9 79 , 000 230 
Alternative 
Pathway 
Components 
Properdin 223,000 25 
Factor B 100.000 250 
Factor D 25,000 Trace 
Control 
Proteins 
Cl- inhibitor 90,000 18 
C3b-inactivator 100,000 40 
C6-inactivator 
SlH globulin 150,000 600 
C4 - binding 
protein Several 540- 590 , 
000 
Anaphylatoxin 
inhibitor 310 , 000 
(Hauptmann, 1979) 
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coded by genes within the HLA region s uggests that they may have e-
volved from a common ancestral gene. 
£o~S!.n~n!.s_Cl.!.n£ £5: Both C3 and C5 consist of two polypeptide 
chains with the sum molecular weight of 180,000 . Both components are 
cleaved into two fragments , the smal l molecular weight C3a and C5a 
responsible for anaphylatoxic and chemotactic activities and the larger 
weight C3b and C5b playing actively in immune cytolysis. 
Parital amino acid sequencing of the small molecular weight frag-
ments C3a and C5a show marked similarities, eight of the first twenty-
five amino acid residues are identical with only minor manipulation in 
positioning of the two peptides (Fernandez et al . 1977) . Anaphylatoxic 
a c tivity of both lies in an intact a r ginine at the C-terminus o f the 
peptide chain . The amino acid sequence similarities and the intact ar-
ginine dependent anaphylatoxic activity are also evident in C4a . The 
anaphylatoxic activity of C4a is of a lesser magni t ude than C3a or C5a . 
£o~£n.!n!.s_C.§. .!.n!! £7: Please see detailed section, page 23 . 
Deficiencies of Complement Components , Disease Association and 
Linkage 
More information pertaining to complement genetics is gained from 
three sources : (i) f r om the study of polymorphism of the individual 
componen ts. 
(ii ) from the study of complement de f iciencies , 
(iii) and from the stu dy of linkage of the components 
to other kn oYn genetic loci. 
The first complement component to demonstrate electrophoretic po-
lymorphism was the slow e protein (Weime, 1965), late r identified as 
C3 (Alper and Propp , 1968). Being a major serum protein , it 1s the 
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only complement protein which can be analyzed by electrophoresis in 
agarose gel followed by direct protein staining. 
In 1972, polymorphism of Factor B was detected by electrophoresis 
in agarose gel and immunofixation with anti-Factor B (Alper et a1. 19-
72a). This method is applicable to other complement components wher-
ever there is sufficient specific antibody available and the concentra-
tion of the component is high enough. 
A means of detecting both polymorphism and functional activity 
was p ioneered by Hobart et al . (1975), in which isoelectric focusing 
in polyacrylamide gel is followed by a hemolytic overlay of erythro-
cytes and hemolytic reagents necessary for detecting the particular 
component in question. First used for C6 allotyping, this method is 
extremely adaptable for the detection of other l ytic proteins, as well 
as the other complement proteins. 
Since the discovery of C3 polymorphism, deficiency or polymorphism 
has been detected in all classical components and in Factors B a,nd D, 
and both states have been used to study the possibility of linkage to 
known genetic markers . 
With the advance of diagnostic techniques, deficiencies of iso-
lated complement components have been detected and these deficiencies 
show association with specific disease states (see Table II). 
fl..:.i!!.h.!.b.!.t~r : The first disease shown to be associated with a ge-
netic abnormality (specifically a deficiency) of a protein in the com-
plement system was hereditary angioedema. This disease is due'to the 
deficiency of the Cl inhibitor and therefore, complement activity is 
unrestrained. The defect is transt'litted genetically as an autosomal 
dominant (Donaldson et a1. 1963; Donaldson et a1. 1977). Defective 
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Table II. Complement deficiencies in man. 
Component Number 
of cases 
(pedigrees) 
Clq 3(2) 
Clr 2(2) 
CJ. 1(1) 
C4 4(4) 
C2 >40 
C3 4(4) 
C5 2(2) 
C6 4(4) 
C6 + C7 1(1) 
C7 
C8 5(2) 
C9 2(2) 
Factor B 14(4) 
(heterozygous 
and/or function-
ally deficient 
Cl inhibitor =ny 
C3b inactiva- 2(2) 
Clinical manifestations 
SLE-like syndrome, renal disease, healthy 
Infection, SLE-like syndrome 
SLE 
SLE-like, glomerulonephritis (abortions) 
About 50% healthy, SLE, immune complex 
disease including Schonlein-Heaoch pur-
pura, glomerulonephritis 
Severe immune deficiencies, fever, arth-
ralgia 
SLE, gonococcal sepsis, healthy 
Gonococcal sepsis, recurrent meningococ-
cal meningitis, healthy 
Healthy 
Glomerulonephritis, gonococcal sepsis, 
meningococcal infection, Raynaud' s di-
sease, rheumatoid arthrits. SLE, heal-
rhy 
Gonococcal sepsis, healthy, SLE-like 
Healthy 
In association with C2 deficiency, 
rent bacterial infections, healthy 
HAE with immune complex diseaset, nephritis 
Severe immune deficiency, recurrent men-
ingitis 
SLE • systemic lupus erythematosus; RAE - hereditat:y angioedema 
(Rittnet: and Bet:trams, 1981) 
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suppression of the normal gene was shown. by the de-repressive effects 
apparent with the use of androgen therapy . With this treatment. Cl 
protein levels rose toward normal in those individuals exhibiting 
either markedly reduced levels of Cl-INH or high to normal levels of 
dysfunctional CI - INH protein (Colten et a1. 1981; Gelfand et al . 1976). 
f.o!!!p.2.n~n!. fl_-_s~bE.n.!t_C.!.q: Deficiencies of subcomponent Clq 
have for the most part been the product of hypercatabolism of CIq in 
patients exhibiting hypogammaglobulinemia (Clq is decreased due to an 
increased catabolism and higher extravascular distribution). with mul-
tiple myeloma and common variable immunodeficiency (Kohler and Huller-
Eberhard. 1972). Rowever. recently two families have been identified 
as antigenically deficient due to a familial defect which results in 
a nonfunctional molecule (Thompson et a1. 1980; Leyva-Cobian et a1. 
1981). Homozygosity of the defective gene has been associated with 
systemic lupus erythematosus (SLE)-like disease and subsequent renal 
disease but may also be associated with health. Detection of the he-
terozygous state by quantitation was difficult. presumably because the 
normal gene contributes more to the serum level of Clq than the abnor-
mal gene. There has been no indication of linkage of the Clq deficien-
cy gene and lD..A (Arnlltz- Villena et al . in press). 
fo.!!!.p.2.n~n!. fl_-_s~b~n.!t_C.!.r : Complement studies revealing no Cir. 
decreased CIs and elevated C4 levels were first described by Pickering 
et a1. (1970). If the Clr molecule is depleted due to activation, C4 
levels are expected to be low and therefore , the defect described was 
an inability to synthesis Clr . 
Deficiency of the Clr molecule has been associated with multiple 
infections, SLE- like symptoms, renal disease and arthritis (Pickering 
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et a1. 1970; Day et a1. 1975: Mittal et a1. 1976). An inherited de-
fect, the autosomal gene controlling Clr deficiency segregated inde-
pendently of the genes of the HLA and ABO systems (Mittal et a1. 1976). 
by Pondman and associates (1968) showing an association with SLE. SLE-
like disease was also evident in the individual described by Blum et 
a1. (1976). Cis deficiency was due to a null gene at the site that 
codes for the synthesis of CIs . No linkage to HLA has been demonstrated. 
fO~.2.n~n!. f4: Complete C4 deficiency, desc r ibed in only four in-
dividuals (Hauptmann et a1. 1974; Ochs et a1. 1977; Ballow et a1. 1979; 
Hauptmann, 1979), was associated with clinical symptoms of SLE and glo-
meru10nephritis . The deficiency 'was inhe r ited as an autosomal co-domi-
nant trait (Hauptmann et a1. 1974) and family studies revealed its lin-
kage to the major histocompatibility complex (Ri ttner et a1. 1975; Ochs 
et a1. 1977). 
fo~.£n~n!. f2: The most common deficiency within the coo:plement 
system is that of the second component. Although about half of the de-
fi c ient individual s were healthy. the deficiency state has been associ-
ated with Hodgkin ' s disease , chronic lymphocytic leukemia, infectious 
fatal dermatomyositis. membranopro1iferative glomerulonephritis and a-
naphylactoid purpura (Day et a1. 1978 ; Gewurz et al . 1978). 
The C2 deficiency gene was closely linked to HLA (Fu et a1. 1975; 
Fu et a1. 1977) and allelic association was apparent between Aw2S, B18 , 
Dw2 and the deficiency gene (Day et a1. 1975; Gibson et a1. lrJ76; Haupt-
mann et al. 1977a). Within the human population, the Aw2S , Bi8, Dw2 
haplotype occur s rarely and approximately 50% exhibit the C2 deficiency 
gene (Mortensen et al. 1980). 
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£0!!!p.2.n~n.! £3: Deficiency of the third component, complete (Alper 
et a1. 1969) or partial (Hoppe et a1. 1978) , is associated with recur-
rent infections since the individual lacks the biological activities 
mediated by this component and those following in the cascade (Alper 
et a1. 1972b; Alper ct a1. 1976). Only four cases of homozygous C3 
deficiency have been described (Alper et a!. 1972b; Davis et a1. 1977; 
Ballow et a1. 1975; Lachmann and Rosen , 1978). 
C3 was also found deficient when the C3 inactivator protein was 
absent. In an inherited deficiency of C3-INA. , the C3 molecules are 
over consumed during pathway activation. Clinical maifestations were 
identical to C3 deficiency in that there was increased susceptibility 
t o infection . Two such cases have been described (Alper et a1. 1970; 
Thompson and Lachmann, 1977) . 
£OE!P.2.n~n.! £5 : First identified i1!Dllunochemically (Rosenfeld et a!. 
1976) , hereditary CS deficiency was not linked to HLA (Rosenfeld et a!. 
1977; Snyderman et a!. 1978; Snyderman et a!. 1979), nor was it linked 
to complement component C6 (Rosenfeld et a!. 1978). The deficiency 
state was compatible with good health but has been associated with SLE 
(Rosenfeld et a!. 1976) and predisposition to disseminat-ed gonococcal 
infections (Snyderman et a!. 1978; Snyderman et a!. 1979). 
£o!!p.2.n~n! £6: Please see detailed section, page 25. 
£0E!P.2.n~n! £7 : Please see detailed section, page 26. 
£0E!P.2.n~n!. £8: Deficiency of C8 seemingly predisposed to gonococ-
cal infection (Merritt et a1. 1976 ; Petersen et a1. 1976 ; Snyderman et 
a1. 1978 ; Petersen et a1. 1979) and the immune-complex disease, SLE 
(Jasin, 1977) . 
HLA linkage was first suggested for C8 (Merritt et a!. 1976; Peter-
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sen et a1. 1976) but was disputed with later family studies (Jasin, 
1977; Giraldo et a1. 1977; Tedesco et a1. 1980). The deficiency gene 
was not found to be linked to the C6 locus (Tedesco et al. 1980). 
fp!!!p.£.n~n!. f.9 : To date, only three individuals have been described 
as having C9 deficiency (Lint et a1. 1980; Ind et a1. 1979) . The 
small number was thought due to the fact that lysis will proceed, 
though slowly, without addition of C9 (Stolfi, 1968). Though bacterial 
killing was 35 times slower than the normal killing time of 3 minutes, 
C9 deficient serum was still capable of killing bacteria (Lint et al. 
1980). Individuals deficient in the ninth complement component would 
therefore be easily hidden . Linkage studies have not yet been described. 
Pol}'l!lorphism of Components and Linkage 
f.4y£lyat£Pb.i.!m: Population heterogeneity of the fourth complement 
component was first suggested by two-dimensional immunoelectrophoresis 
of EDTA- plasma against anti-C4 serum (Rosenfeld et a1. 1969; Bach et 
a1. 1971). Subsequent work using the technique of high voltage electro-
phoresis in agarose gel followed by immunofixation was used to reveal a 
true C4 polymorphism (Teisberg et a1. 1976; Hauff et a1. 1978). The 
current method in which better separation of the C4 protein bands was 
found, entails pre-treatment of serum samples with neuraminadase before 
high voltage electrophoresis and immunofixation (Awdeh and Alper, 1980) . 
C4 allotyping of family groups has since the beginning given data 
which are not wholly compatible with the concept of a single co-domi-
nant autosomal locus . Immunochemical and genetic data led O'~ill et 
al. (1978a; 1978b) to suggest that two loci may code for the C4 protein 
on each liLA haplotype and that the antigens of the Chido and Rodgers 
blood groups are components of C4 . One locus, A, having 7 alleles which 
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have faster electrophoretic mobility than the 3 at the B locus, appears 
to code for molecules that are Rodgers positive and Chido negative. 
The B locus alleles are Rodgers negative and Chido positive. One allele 
at the A locus may be hemolytically inactive and shows allelic associa-
tion with HLA-BI7 (O'Neill et al. 1980) . Null alleles presumably exist 
for both loci as evidenced by complete C4 deficiency and are postulated 
by O'Neill to occur frequently. Other workers are more conservative 
and simply conclude that duplicated loci exist on some haplotypes hut 
cannot be demonstrated yet on others. Homozygosity for null genes at 
both loci may perhaps be selected against since there have been so few 
complete C4 deficiencies observed (see C4 deficiency, page 17) . The 
most common haplotype is A3Bl and accounts for approximately 80% of the 
population (Skanes, personal communication) . 
Strong alleleic association has been shovn between HLA-B types and 
C4 (Teisberg et a1. 1977) and between C4 and Bf but not between C4 and 
GLO-I (Hauff et a1. 1978). Therefore, the two loci for C4 are consi-
dered to be within the HLA complex and close to Bf and HLA-B, a conclu-
sion which is supported by limited data on recombinants. 
f2y£lym£FE.h.!s.!!: First described by Hobart and Lachmann (1976a), 
the C2 polymorphism revealed close linkage between the C2 locus and 
HLA. Isoelectric focusing in thin-layer polyacrylamide gel. followed 
by a hemolytic overlay deficient in C2, revealed three alleles for the 
second component. C2*I, the most common , had a frequency of approxi-
mately 0.96 (Meo et a1. 1976; Meo et a1. 1977; Alper , 1976; Oleisen et 
a1. 1978a; Harsh!lll et a1. 1980a). Family studies suggested close 
linkage between C2 and HLA/Bf (Allen, 1974; Alper, 1976). 
f3_p£lym£r.£h.!s,!!: The high concentration of C3 in serum aids in 
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its ease of allotyping. The protein can be visualized after high vol-
tage electrophoresis in agarose or starch gels by simple staining . 
C3 polymorphism is controlled by a single autosomal locus and there 
are two common co-dominant alleles and at least 22 rare ones. The 
mo re common allele, C3S , has a frequency of 0.77 to 0.81 in Caucasians . 
The faster migrating common allele, C3F, occurs at a frequency of 0 . 18 
to 0.21 in Caucasian populations (Hauptmann, 1979). Population studies 
have shown a higher frequency of C3S in Negroid and Mongoloid popula-
tions as compared to Europeans (Seth et a1. 1976) and a very high fre-
quency of C3S in Lapps (Teisberg, 1971) . The total. frequency of rare 
variants varies between 0.004 and 0.1, except in the Lapps and Finns 
where no rare var iants have been identified (Seth et a1. 1976). 
Although the C3 structural locus was found close to the histocom-
patibility complex H-2 in the mouse (Natsuume-Sakai et a1. 1978; Penalva 
da Silva et a1. 1978), extensive studies had not linked human C3 to any 
firmly established linkage group (Gedde-Dahl et al . 1974; Lamm et al. 
1975; Weitkamp et a1. 1975), other than a suggestion of loose linkage 
between the C3 locus and those of the Lewis b l ood group (Weitkamp et 
a1. 1974) and familial hyper cholesterolemia (Ott et a1. 1974) • 
.f5YE,lymE,r.E.h.!.s!!!.: Isoelectric fOCUSing followed by hemolytic over-
lay revealed no polymorphism in any population studied (Rosenfeld et a1. 
1977; Vas-Guedez et al . 1978), except that of the Melanesians (Hobart 
et a1. 1981). Two co-dominant alleles exist; C5*I , the most common with 
a frequency of 0.93 and C5*2, with a frequency of 0.07. Linka8:e data 
had not linked the C5 locus to HLA or C6/C7 • 
.f6YE,lymE,r.E.h.!.s.!!!.: Please see detailed section, page 28. 
f?yE,lymE,r,£hls!!!.: Please see detailed section, page 35 . 
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f8J£lzm£r£.h.!s:!! : Genetic polymorphism of C8 had only recently 
been reported by Alper et a1. (1979) . Isoelectric focusing and hemo-
l y tic overlay revealed two alleles, A and B, and a third allele, AI, 
dete cted only in Blacks. 
!8.£t£r_ BJ£1zt1l;Q.r£.h.!s:!!: A functionally deficient variant was found 
of Factor B (Mauff et a1. 1980) and polymorphism of Factor B has been 
s tudied since 1972 (Alper et a1. 1972a) , showing the locus to be close-
l y linked to HLA (Allen, 1974; Olaisee. et a1. 1975; Rittner et a1. 1975; 
Rittner et a1. 1976a; Albert et a1. 1977; Larsen et a1. 1977; Bender 
et a1. 1977; Arnason et a1. 1977). Polymorphism was detected by agarose 
gel electrophoresis and immunofixation . Functional activity of the 
var i ants was realized by employing hemolytic overlay. There are two 
c ommon alleles, F and 5, and two less common, Fl and 50.7 described 
(Alper et a1. 1972a) and there are at least seven very rare alleles 
(Hauptmann et a1. 1976: Naff et a1. 1976; Hauptmann et a1. 1977b; Larsen 
et a 1. 1981). 
The Bf l o cus was thought to be close to that of HLA-B since signi-
ficant associations had been found between BfS and alleles B7 and B8; 
between BfF and B12 and Bw35: between BfSO.7 and Bw50 and between BfFl 
and B18 (Olaisen et a1. 1975: Rittner et a1. 1975; Bender et a1. 1977; 
Larsen et a1. 1977; Arnason et a1. 1977) . 
lay deficient in Factor D revealed a single banded pattern. Variants 
have been observed only in African samples (Hobart and Lachamn~, 1976a; 
Marshall, personal communication). 
~~rz: Information on the genetics of complement, obtained from 
studies of deficiency and polymorphism of the individual components, 
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suggests that the components actively forming the C3-convertases (C4, 
C2 and Factor B) are linked to the major histocompatibility complex. 
and deficiencies of these components predispose particularly to SLE-
like syndromes . The exact position of the loci for C4 , C2 and Factor 
B is still unknown . Host evidence suggests a tentative map with the 
loci between HLA-B and HLA-D/DR , c l oser to B, as shown in Figure II. 
Studies of the l ate acting components do not suggest linkage to lILA 
or to any other known marker and are thus far not assigned to any 
chromosome . 
THE GENETICS OF COMPLEMENT COMPONENTS C6 AND C7 
A genetic relationship has been proposed on the basis of similar-
ities in phySical and chemical properties and functional activities for 
Clr and CIs; C3 , C4 and C5 ; and C2 and Factor B. C2 and Factor B have 
been found to be linked with each other and with HLA (Fu et al. 1977; 
Allen, 1974). Genetic linkage has also been p r oposed between C6 and 
C7, the suggestion substantiated by physicochemical similarities (Podack 
et a1. 1976; Podack et al . 1979) , combined deficiency (Hobart and Lach-
mann, 1978; Glass et al. 1978) and polymorphism studies of the two pro-
teins (Hobart et a1. 1978) . 
Similarities Between C6 and C7 
C6 and C7, isolated and pur ified from human serum with immunoabsor-
bent columns of Sepharose coupled with anti- C6 IgG and anti-C7 IgG, are 
almost indistinguishable by amino acid composition . Only fo ur amino 
acids; aspartic acid , isoleusine, lysine and proline, differ by more 
than 1 mole percent. Although no sequence data are available, a degree 
of homology Is expected (Podack et a1. 1979) . Determined to be single 
polypeptide chians (Podack et al . 1976) , both are glycoproteins (Podack 
CHROMOSOME 6 
~C2,C4,Bf~ 
0( IR,IS~ 
Figure II. A tentative map of Chromosome 6. IR = immune response genes. IS -
immune suppressor genes. GLO - glyoxylase I. PGM3 - phosphoglucomutase 3. 
(Rittner and Bertrams, 1981) 
, 
~ , 
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et a!. 1979). The molecular weights are calculated from amino acid 
composition; 124,801 for C6 and 120,806 for C7, and are similar to 
those found earlier (Arroyave and Muller-Eberhard, 1971; Podack et al. 
1976). Upon isoelectric focusing, the major bands of C6 focus at pH 
6.4; those of C7 at pH 6.25. Circular dichroism spectra show similar 
secondary structure in that both molecules contain 20 to 30% a-helical 
and S-structure (Podack et a1. 1979). 
These similarities in the physicochemical properties of C6 and C7 
support the theory that the two proteins are the product of gene dupli-
cation (Hobart and Lachmann, 1976a; Lachmann and Hobart, 1978a). 
Deficiency of C6 and C7 I Disease Association and Linkage 
fo!!!.p.2.n~n.! f6: First described by Leddy et a1. (1974), C6 defi-
ciency was repeatedly shown to increase susceptibility to recurrent 
infections due to a lack of bacteriolytic activity against organisms 
such as Neisseria gonococcus and Neisseria meningitidis (Lim et a1. 
1976; Vogler et a1. 1977; Glass et a1. 1978; Lee et a!. 1979 ; Petersen 
et a1. 1979; Vogler et a!. 1979; Clough et a!. 1980; Haeney et a1. 1980). 
To date, only one study had implied that C6 deficiency predisposed to 
connective tissue disease such as discoid lupus and Sjogren's syndrome 
(Trapp et a1. 1980). 
Chemotactic and opsonic activities were normal in these individuals 
and unlike C6 deficient rabbits, there was no visible clotting abnor-
mality. the thrombin consumption time lying in the upper range of nor-
mal (Heusinkveld et a1. 1974; Delage et a1. 1977). The hemolytic acti-
vity of C6 deficient serum was restored by addition of purified C6 . 
Genetic analyses suggested a co-dominant Mendelian inheritance of 
the trait. Originally thought to be HLA linked with a strong associa-
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tion with HLA-Aw24 (Raum et a1. 1976) , more recent studies have repeat-
edly shown no segregation of the HLA complex genes with that of C6 de-
ficiency (Mittal et a1. 1976; Clough et a1. 1978; Vogler et a1. 1979; 
De1.age et a1. 1979; Haeney et a1. 1980; Trapp et a1. 1980). Also, with 
t he identification of a family having a combined deficiency of C6 and 
C2, it was determined that the deficiencies were two distinct heredi-
t a r y defects , independent of one another (Delage et a1. 1979) • 
.f.0~.2.n~n.!. .f.7 : As with C6 deficiency, the absence of the seventh 
c omponent of complement was generally associated with recurrent infec-
tions caused by N. gonococcus and N. meningit.idis (Lint et a1. 1976 ; 
Lee et al. 1977; Lee et al . 1978; Lambert et al. 1979; Loirat et al. 
1980) but was also associated with SLE (Zeitz et a1. 1978), nephritis 
(Nemerow et al . 1978) and arthritis (Alcalay et a 1. 1980). C7 defi-
cient sera showed no lack of opsonic or chemotactic activity nor of 
immune adherence, but bacteriolytic activity was absent . Early basic 
blood coagulation studies reported no abnormality (Boyer et a1. 1975; 
Delage et a1. 1977) but recently C7 deficient serum was shown to deter-
mine a disorder in platelet aggregation in the presence of thrombin. 
The abnormality was correctable by the addition of purified C7 (Alcalay 
et a1. 1980). 
Wellek and Opferkuch (1975) reported a C7-inactivating principle 
in the serum of a healthy patient functionally and antigenically defi-
cient in C7. 
A single individual has been identified as deficient for \loth C2 
and C7. Family studies revealed that both parents had transmitted 
their own singular deficiency and therefore the deficiencies are inde-
pendent of one another. 
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.fo~b .. !:.n~d_d~f.!c.!e.!!cy 2..,f_Ci !.n~ .f7: 1\.10 families have been shown 
to be simultaneously deficient in both C6 and C7 (see below), giving 
support to the theory that the genetic loci of these structurally si-
milar proteins are closely linked .. 
There are a number of possible mechanisms by which a genetic de-
fect could result in a combined deficiency .. A l arge deletion within 
the region of the two structural genes could result in transcription 
of neithe r protein . Conversely , a smaller deletion could overlap the 
two genes such that various outcomes could reasonably occur .. Concei-
vably , both proteins could be abnormal, either or both showing some 
function; or one protein could be abnormal while the other not made ; 
or a protein comprising the N-terminal end of one protein and the C-
terminal end of the other protein could be made. This "Lepore" mole -
cule might show some function of either or both parent proteins . Al-
ternatively , a defect in the structura l gene of one protein could have 
a secondary effect on the structura l ly normal second protein, in that 
its synthesis could be affected or it could be hypercatabolized by a 
reaction with the abnormal protein. Deficiency could also be due to 
an effect of a control gene such that the synthesis of structurally 
normal proteins is affec t ed , or due to the presence of an inactivating 
protein. 
A family examined by Lachmann and co-workers (l978b) centers upon 
one gentleman who was in general good health but had low but detectable 
amounts of C6 and C7 . The C6 molecule was antigenically defic~ent and 
was smaller than normal C6 .. The C7 molecule was normal both antigen i -
cally and structurally.. Thus, the combined deficiency being due to 
a mutation at the level of a control gene is unlikely.. A thr ee gener-
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ation study of the gentleman's family showed the deficiency to be 
inherited together as a single Mendelian trait. as is seen in Figure 
III. Heterozygotes had half levels for both the C6 and C7 proteins . 
Hemizygosity at the C6 locus was confirmed in the grandchildren in 
that those children who carried only the paternal C6B allele had half 
levels of both C6 and C7 while those who were phenotypically C6AB had 
normal levels. 
Rapid in vivo catabolism of the normal C7 by the abnormal C6 can-
not be excluded as a possible explanation for the combined deficiency 
but the more probable mechanism by which such a combined deficiency 
would occur is that a structural mutation at the C6 locus affects the 
rate of synthesis at the closely linked C7 locus . If the C6-C7 region 
is transcribed as a single message, a mutational event at one locus 
could conceivably interfere with transcription or post-transcriptional 
events at one or both loci. This explanation is applicable to the co-
existent partial deficiency of C6 and C7 evident in the family present-
ed by Glass and co-workers (1978) , Figure IV. Functional and immuno-
chemical assays did not detect synthesis of a dysfunctional protein. 
All the family members with low levels of C6 also had low levels of C7 . 
Conversely. all those with normal C6 had normal C7 levels. 
C6 Polymorphism 
Electrophoretic variation of C6 has been demonstrated in rabbits 
(Goldman et . a1. 1981), dogs (Hobart, personal cOllllllunication) I, and primates 
(rhesus monkey. Hall et a1. 1977; chimpanzee, Raum et a1. 1980), including 
man (Alper et a1. 1975; Hobart et a1. 1975; Hobart and Lachmann, 1976a; 
DIving et a1. 1977 ; Rittner et a1. 1979; DIving et a1. 1979). 
1. Postal strike prevented receiving written unpublished data . 
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Figure III. Family having combined C6-C7 deficiency. Levels of allotypes of C6 
are shown. Levels of C7 are shown. No allotype other than C7 1-1 was found. HLA 
types are shown where they were obtained. They are not informative for this fam-
ily. (Laclunann et a1. 1978) 
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Figure IV. Family having co-existent partial deficiency of C6 and C7. (Glass et al. 1978). 
The half filled symbols are members with reduced C6 and C7 concentrations . 
NT. ;; Not tested. 
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.f6y£lym£.r£.h.!s~ .!n_r,!!.b~i.!.s: The control of the structural vari-
ants of C6 in rabbits was studied by quantitation of functional and 
antigenic C6 levels and isoelectric focusing (Goldman et a1. 1981). 
Three alleles were found, C6*A, the more acidic protein, C6*B, the more 
basic and C6*QO, having no functional or antigenic activity. Hetero-
zygotes of C6AQO or C6BQO had half levels of C6 protein and matings of 
heterozygotes produced the expected phenotypes and C6 activity levels, 
demonstrating that the two variants, C6*A and C6*B and the deficiency 
gene, C6*QO are allelic at the same genetic locus . 
.f6y£lym£r'p'h!s~ ..!ny!.i!!l}i.!.e~: In the chimpanzee (Raum et a1. 1980), 
the most common allele , C6*C, migrates to a slightly more basic isoelec-
tric point than that of a reference human C6*A. Other alleles , C6*A 
and C6*B, respectively more acidic and more basic than the common al-
lele, and different basic alleles were also demonstrated. Also, a 
blank allele confirmed immunochemicallY was not uncommon in the chim-
panzee. 
Polymorphism of C6 in the rhesus monkey was much like that found 
in man (Hall et a1. 1977) . Two major alleles, C6*A (frequency '" 0.592) 
and C6*B (frequency'" 0.354) and a single rare variant, C6*R (frequency 
- 0.053), were demonstrated by isoelectric focusing and hemolytic over-
lay . Natural mating between monkeys having the various alleles demon-
strated that the three alleles were co-dominant and of a single locus. 
Itlt'erestlngly, t he alle1.ic frequencies of the rhesus monkey were not 
unlike those found in man • 
.f6y£lym£r£.h.!s~ .!n_m,!!.n: Of the human populations studied, all have 
exhibited two major alleles, C6*A and C6*B, which occur with only slight 
differences in frequencies between the ethnic groups. Rare alleles have 
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been observed in all populations except those of India (Hobart and 
Lachmann, 1976a) and the Norwegian Lapps (DIving et al . 1979). The 
first study of Norwegians (non-Lapps) demonstrated no rare variants 
but further investigation yielded a combined frequency of 0.004 (01-
ving et a1. 1979) . Since only thirteen individuals were allotyped in 
the Indian population and because the frequency of rare alleles is 
small, the Indian study may not be indicative of the true frequency of 
rare variants within the population. Comparisons of C6 allele fre-
quencies in various populations are given in Table III. 
The common alleles code for proteins whose patterns differ by a 
single step in the banding pattern; C6*A being the more acidic pattern, 
C6*B, the basic. There have been 6 rare variants identified so far, 
coding for proteins which are not shifted a total pattern step. These 
patterns are shown schematically in Figure V. 
The single step difference in the banding pattern of C6*A and C6*B 
can easily be produced by high voltage electrophoresis in agarose gel 
(DIving et a1. 1977). Rare alleles are still more easily identified 
by using the principle method of isoelectric focusing in thin-layer 
polyacrylamide gel (Hobart et a1. 1975). Regardless of the method of 
protein separation, visualization of the banding is usually through the 
use of a functional overlay of antibody sensitized sheep red blood cells 
and- C6 deficient rabbit serum in agarose. 
It is pOSSible, through studying the inheritance of the C6 alleles 
within a family in which some members have low C6 serum levelS', to 
determine the relationship between the structural genes and the defi-
ciency. In four informative families (Glass et al. 1978), the genes 
determining electrophoretic variants and the low serum levels of C6 
Table III. C6 allele frequencies in various populations 
Population Allele frequencies References 
C6*A C6*B C6*R 
Caucasians British and 189 0.621 0 . 360 0 . 018 Hobart and Lachmann , 1976a 
N. American 
British 99 0.61 0.37 0.015 Hobart et a1. 1975 
British 264 0 . 646 0 . 333 0.021 Alper et a1. 1975 
Norway 81 0.61 0.39 0.0 Olving et a1. 1977 
Norway 1623 0.59 0.379 0.004 Olving et a1. 1979 
Germany 194 0 . 613 0.379 0.008 Rittner et a1. 1979 
India 13 0 . 5 0.5 0.0 Hobart and Laclunann, 1976a 
Lapps Norway 167 0 . 53 0.47 0.0 Olving et a1. 1979 
Mongoloid N. America 51 0.59 0 . 35 0.05 Hobart and Lachmann, 1976a 
Negro N. America, 
W. Indies, 
and Nigeria 165 0 . 551 0 . 403 0.045 Hobart and Lachmann , 1976a 
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were considered to be heterozygous for a normal gene and a silent or 
"null" gene which was the result of a mutation at the structural locus . 
These findings echoed similar suggestions made by Hobart and Lachmann 
(l976b) • 
The high gene frequencies of the major alleles of C6 make it: a 
useful marker and in Germany, C6 polymorphism has been applied to pa-
ternity cases (Rittner et a1. 1979). 
There is no significant evidence for linkage betwen the C6 struc-
tural locus and any marker tested (Hobart et al . 1977; DIving et al. 
1977; Olving et a1. 1978; Olaisen et a1. 1978b; Kagan et a1. 1979; 01 -
ving et a1. 1979). including m..A. Gm. C3 and many red cell antigens 
and enzyme markers (see Figure VI), nor is C6 l inked to C5 deficiency 
(Rosenfeld e t a1. 1978). Small positive lod scores for Gm (0.23 at e -
0.20) . Gc (0.24 at e - 0 .10) and AKI (0.26 at e - 0.20) (Hobart et a1. 
1977). were convincingly demonstrated as insignificant when taken in 
conjunction with the extensive study by DIving et a1. (1979), as is 
illustrated in Table IV . Table V condenses results from the two studies 
(Hobart et a1. 1977; DIving et a1. 1979) wherever positive lod scores 
were obtained in males. The positive lod sco r e at e - 0 . 20 for P-C6 
linkage (DIving et a1. 1979) was obtained from two generation families 
only . Three generation families would be necessary to verify linkage 
at such a distance. The only locus for which there is good evidence 
of linkage to C6 is the structural locus of C7 (Lachamnn and Hobart . 
1978a; Lachmann et a1. 1978b: Hobart et a!. 1978: Glass et a!. ' 1978) . 
C7 Polymorphism 
Screening of random samples by isoelectric focusing in thin-layer 
polyacrylamide gel enabled the identification of three structural forms 
Chromosome 
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000 020 RF 
0.10 RF 
Figure VI. Diagram showing the parts of the male genome 
from which C6 has been excluded (lad score <-2.00). 
(Dlving et a1. 1979) 
Table IV . Combined lod scores for Gm, Gc and AK1 . 
Locus Reference 
Gm DEd.ag et a1. 1979 
Hobart et a1. 1977 
Combined 
DIving et a1. 1979 
Hobart et a1. 1977 
Combined 
Sex . of-------rwC;- and three generation data; lod scores for 
Hetero- recombination fractions of : 
zygote 0.05 0 . 10 0.20 0.30 0.40 
M - 6.20 - 3.62 -1. 47 -0 . 58 -0.17 
6.29 - 3.32 -1. 00 -0.21 - 0.01 
M .. _;H,;,~2 .... __ .. ;§.;,2~ __ ..... ;~_~Z .. ..: ...... ;Q.:.Z2 _____ ;g_!~ ........ 
- 10.86 -6.15 -2.34 - 0.67 -0.12 
-5.27 -2.00 +0.23 +0.16 +0.12 
___ !.2_!1 __ .. __ ;§_lz _____ ;~_!! _____ ;Q .:.~1 ______ 2_QQ. __ ,. 
____ •••••• _~~~2.!~!li2_t:_±_f ______________ ;~§.:..2~ ____ ;1~_Q2 _____ ;~_~§._ .. ,. .. ;!.:.~Q __ .... "';;;Q.:.!§ ___ _ 
Gc DIving et a1. 1979 M -5.70 -3.31 -1.30 - 0.47 -0.15 
Hobart et a1. 1977 M - 6.55 -3.54 -1.15 -0.31 -0.05 
Combined M 12.25 -6.85 -2.45 -0.78 -0 . 20 
DIving et a1. 1979 ----:'8:C)'r-----:4:66-.. · .. --:i':'i3o .... ---:o':''6i-.. ---:o':'ij= .. == 
Hobart et a1. 1977 -0.31 +0.25 +0.50 +0.38 +0.19 
Combined ____ §.:.1§ ___ .. _;~.:.:! ____ "';! .. 1Q"' .. _ ... ;Q=~~ .. "' .... "'±2.:.~.2"' .. _ .. 
_______ . _ •• ~s:~~.!!!!li2_t1_±_f .. _____ ........ _ ...... :~Q,;, .2~ .... _ .. ;!!,;,a§ _____ ;~.;.Z~ _____ ;!.:.Qa _____ ;Q.:.H ___ _ 
AK, Olving et a1. 1979 M 
Hobart et a1. 1977 M 
-1.44 -0.89 -0.38 -0.15 -0.04 
- 3.26 -1.15 +0.26 +0.46 +0.22 
Combined M 4.70 - 2.04 -0.12 +0.31 +0.18 
DIving et a1. 1979 ---:Z':'3j-----:i':'6S-----:i':'5g-----:5':'45-----:5':'5g----
Hobart et a1. 1977 3.72 - 1.96 - 0.57 -0.11 -0.02 
Combined _ .. _;§,;,~~ _____ :~.:.§~ __ .. __ :!.:..2§ ____ .. ;Q.:.~! _____ ;Q.:.!! ___ _ 
CQIDb1ned_M_±_L -12.95 - 6.68 - 1.78 -0.20 +0 . 07 
, 
w 
, 
Table V. Joint lad sco r es for C6 linkage relations with positive lad scores in one of the 
two published materials , males only 
Sour ce of data Male C6 lad scores to marker loci 
AKI ABO HP K Km ACPl ESO ADA MNSs P 
("",,.3) (6- 0.3) (6-0.4) (6-0 . 3) (6- 0 . 3) (6-0 . 3) (6=0 . 4) (6-0.05)(6=0.3) (6-0.2) 
Hobart et a1. 1977 +0 . 46 +0 . 14 +0.21 +0 . 26 +0.16 -0 . 53 -0.21 -8 . 02 -0.18 -0 . 18 
Olving et a1. 1979 - 0.15 - 0.40 -0.18 - 0.24 - 0.90 +0.67 +0.10 +0.84 +0.47 +0 . 19 
Both +0 . 31 -0.26 - 0 . 03 +0.02 - 0 . 74 +0.14 -0.11 -7. 18 +0 . 29 +0.0 1 
The comparable recombination fractions--Wfthhighest positive lod scores are used; e1 values 
are given in brackets. 
(Olving et a1. 1979) 
, 
~ , 
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of C7 proteins (Hobart et a1. 1978). C7*I, C7*2 and C7*3 are products 
of three codominantly expressed alleles at a single autosomal locus. 
The banding patterns of the homozygote and heterozygote states are 
shown schematically in Figure VII. 
The homozygote pattern C7 1-1 is by far the most cOUlmon pattern. 
The less common alleles of C7lt 2 and C7 lt 3 have only nominal charge dif-
ferences compared to the COUDD.on allele, resulting in very small changes 
in the pI of the proteins . The structural changes may be a substitution 
of one neutral amino acid with another having a different side chain 
which slightly changes the charge on a neighbouring residue. 
The bands of C7 lt l and C7lt2 were of equal intensity but interesting-
ly. those of C7*3 were found to be relatively weak and therefore posed a 
problem in that they may have been missed on a cursory inspection of the 
gel. Because of this difficulty in detection of the third allele, the 
gene frequencies were not calculated but it was believed that the fre-
quency for both C7*2 and C7*3 was less than 0.01 (Hobart et al. 1978). 
The largest contribution of evidence linking the loci of C6 and 
C7 was a single study of the polymorphic proteins of C7 and their mode 
of inheritance in reference to that of the C6 alleles (Hobart et a1. 
1978) . The family tree as given, is shown in Figure VIII. The C6 and 
C7 genotypes for the first generation were reconstructed from their off-
spring. It is highly improbable that both were heterozygous for C7. 
Assuming the first generation has been correctly genotyped. there are 
ten informative children : II-I, 3. 7, 9; 111-4. 12. 13. 14; ' and indi-
viduals 11- 5, 10 (who are inferred informative through their offspring), 
and there are no recombinations. The C6*A/C7*2 genotype has been inherit-
ed as a single unit. The odds in favour of linkage between C6 and C7 are 
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+ 
Figure VII. Schematic representa t ion of homozygous and heterozygous 
patterns of the major bands of C7. 
[0, b] • [C, dJ[~'~J • [~~~B] 
Figure VIII. Family tree showing C6/C7 linkage. The first generation has been re-
constructed. HLA haplotypes for the first generation are shown as a, b, c, d and 
other haplotypes are omitted. (t) deceased. (a) A2, B17; (b) Aw32. Bw22; (c) Aw24 , 
B40; (d) AIO, B27. (Hobart et a1. 1978) 
, 
~ 
, 
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suggested by the authors as greater than 1000:1. 
The phase of the first generation is unknown but assuming linkage 
of lD..A and C7 , there are five recombinants and nine non-recombinants. 
Therefore, the C7 locus cannot be situated close to the HLA region. 
This is certainly expected since c6 has been shown to be not linked to 
lD..A (Hobart et a1. 1977; DIving et a1. 1977; DIving et a1. 1978; Olaisen 
et a1. 1978b; Dlving et a1. 1979). 
C6/C7 Linkage Summary 
C6 and C7, as precusors of the membrane attack unit, act sequen-
tially in the complement cascade . They share close physicochemical 
properties. Polymorphism has been demonstrated for both proteins and 
it has been further shown that the loci of the two components are 
closely linked. Two families exhibiting combined deficiency of C6 and 
C7 suggest that a single primary transcript is made for both loci. 
Post-transcriptional modification results in translation of two sepa-
rate molecules. Based on all these findings, it is plausible to regard 
C6 and C7 as products of tandem gene duplication . 
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CHAPTER I I OBJECTIVES 
The general objective of this thesis is to contribute t o the pre-
sently limited pool of information pertaining to the genetics of human 
C6 and C7 . This is accomplished through typing various collections of 
sera available in this l aboratory for C6 and C7 in order to: 
(I) see which alleles are to be found in the sera . 
(2) establish allele frequencies for Newfoundland. 
(3) examine Mendelian ratios , looking particularly for irregular-
ities which might suggest a more complicated genetics than one locus . 
(4) check that rare alleles are inherited and not acquired . 
(5) examine the data for its possible use in genetic linkage stu-
dies , with particular reference to families informative for both C6 
and C7 so that the link between these loci can be examined further and 
to families in which a new marker exists which has not yet been exa-
mined fo r linkage to C6 or C7. As an example of a l inkage investiga-
tion, the linkage of C6 with m..A will be re-examined. 
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CHAPTER III MATERIALS AND METHODS 
The samples for this study were derived from three sources . The 
first, the West Coast connnunity, was under study due to an increased 
frequency of connnon variable illllIlunodeficiencies , Hodgkin's disease and 
other malignancies, in hopes to define a genetic basis for the develop-
ment of such disorders (Buehler et a1. 1975; Marshall et a1. 1980b; 
Salmon et a1. 1980). This community was visited for blood collection 
on four separate occasions. The sera collected in 1974 and 1975 were 
separated from the clot within 24 hours f nd have been kept at _200C 
since then. The sera collected during the visits of 1976 and 1979 
were separated within 4 hours , frozen in liquid nitrogen and stored 
frozen thereafter at -70oC. Sera were available for 1075 individuals 
from the community . The second collection included Newfoundland fami-
lies plus random individuals; the family units usually under genetic 
investigation due to the necessity of kidney or bone marrow transplants, 
or for diseases ·such as ankylosing spondylitis, polycystic kidney di-
sease, urolithiasis or diabetes. Samples of serum or heparin- plasma 
were separated and stored frozen at - 700 C within approximately 3 hours 
of collection. The third collection consisted of an extended Labrador 
family of 110 members, 33 of whom have myotonic dystrophy (Larsen et 
a1. 1979 ; Larsen et a1. 1980). Heparin-plasma samples were separated 
and frozen in liquid nitrogen within 2 hours of collection and stored 
thereaf ter at - 700C. 
A small number of other samples were available from South Africa 
(through the kindness of Dr. M. Hammond) and from mainland China 
(through the kindness of Dr. S.N. Huang). 
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Protein Separation 
The polymorphic C6 and C7 proteins of human complement are sepa-
rated by isoelectric focusing in thin-layer polyacrylamide gel and de-
tection of the resulting banding is through the use of an appropriate 
overlay (see below) . Because these two complement components have 
similar isoelectric focusing points. gels of identical chemical compo-
sit ion (see below) may be used. The slab gels used in this laboratory 
are ultra-thin; of obvious economic benefit but use of such gels also 
results in crisper bands of better separated proteins (Massi et a1. 
1979) . 
Preparation of Ultra-thin-Iayer Polyacrylamide Slab Gels 
To prepare four, approximately IS cm . X 20 . 5 cm. X 0 . 05 cm. slab 
gels, the following materials are needed: 
60.0 mI . stock acrylamide solution (see below) 
1.0 ml. ampholine pH 5- 7 (LKB, 40% wlv, Fisher Scientific 
Ltd., Whitby, ON) 
O.S ml. ampholine pH 6-S (LKB, 40% wlv, Fisher Scientific 
Ltd. , Whitby, ON) 
0.2 ml. ampholine pH 3.5-10 (LKB, 40% wlv, Fisher Scien-
tific Ltd., Whitby, ON) 
30 . 0 Jll. TEMED (Eastman Kodack Co., Rochester, NY) 
16.0 mI . 1 mg.% riboflavin (Sigma Chemical Co ., St. Louis, MO) 
The above chemicals are combined, in the order above , in a vacuum 
flask and de-gassed with swirling for five minutes or until no bubbles 
form on the flask bottom. The de-gassed solution is poured between two 
glass plates with the aid of a pipette and any bubbles are removed by 
gentle tapping. One glass plate (16 . 5 cm. X 21 cm . ) is covered with 
self-adhesive transparent vinyl and gasket (four layers of 0.5. cm. wide 
vinyl), permanent1y bound to the plate . The second plate (16.4 cm. X 
21.5 cm . , glass prepared for coating, treated both sides, Ilford Nu-
clear Research, Markham, ON) is clamped to the covered plate and will 
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form the support for the gel . 
Polymerization of the acrylamide mixture is initiated by direct 
light and is complete in approximately 2\ hours. The plates are pried 
apart and the polymerized gel and its support plate are wrapped with 
plastic wrap and cured at 40C overnight. 
Preparation of Stock Acrylamide Solut i on 
To prepare 500 . 0 ml. stock acrylamide solution, the following 
materials are needed: 
16.68 g. taurine (BOH Chemicals, Toronto, ON) 
33 . 3 g . acrylamide , enzyme grade (Eastman Kodack Co .• 
Rochester, NY) 
0 . 9 g. N-N'-methylene-bisacrylamide (Eastman Kodack Co., 
Rochester, NY) 
The taurine is dissolved with gentle heating and stirring in ap -
proximate l y 300 mI . distilled water . The acrylamides are added · and 
dissolved and the solution made up to 500.0 ml. in distilled water . 
This stock solution is r efrigerated at 4°C in a clean glass bottle 
covered with foil wrap. (The taurine is incorporated in the stock 
sol ution so that t he slab gels are isotonic for the detecting cells 
used in the hemolytic overlay . ) 
Preparation of Gel for Isoelectric Focusing and Application of 
Materials needed: 
cured polyacrylamide slab gel 
sample papers, 6 mm. X 12~. (Whatman 40) 
samples, quick-thawed at 37 C, on ice 
electro focusing str i ps (LKB , Fisher Scientific Co., Whitby, 
6N) 
anode solution, 1 M H3P04 (Fisher Scientific Co ., Whitby . ON) 
cathode solution, 1 N NaOH (SDH Chemicals , Toronto , ON) 
Gilson pipetman, p20 (Mandel Scientific Co . Ltd., Rockland, ON) 
pipette tips 
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For each slab gel, one electro focusing strip is wet with anode 
solution , another with cathode solution and are then placed on the gel , 
approximately 1.5 cm. in on the lengthwise edges of the support plate. 
Sample papers are placed approximately 5 cm. from the anode strip and 
3-6 \.11. of sample is applied pet: paper . The smaller sample of 3 1-11. 
is best as protein overload causes streaking and the homozygous C6BB 
may be mistyped as the heterozygous C6AB. 
Because the homozygous C7*1 pattern is most common, samples may be 
screened for C7. This entails using sample papers of 2 mm. X 18 mm., 
placing the papers very close together on the gel and using 2 1-11. of 
sample . The C7*2 and C7*3 patterns are easily distinguished from the 
common bands and this method allows more samples to be isoelectrically 
separated at one time. 
Electrical Details of Isoelectric Focusing 
Isoelectric focusing is car r ied out at 20 watts constant po...,er, 
maximum voltage of 1500 volts (LKB 2103 Power Supply, Fisher Scientific 
Ltd ., Whitby, ON) with cooling (Pharmacia Fl atbed Apparatus FBE- 3000, 
Dorval, PQ). The out port flow temperature is approximately SoC through-
out the focusing time , higher temperatures causing waving of the band-
ing patterns and lower temperatures increasing protein viscosity . 
The pH gradient is formed within the gel during the first half hour 
and is monitered by the increasing voltage and decreasing amps . Focus-
ing of the C6 protein requires approximately 3~ hours af t er the pH gra-
dient has been establ ished, t he C7 protein about 1 hour less du~ to its 
lower pl . 
C6 Detection 
Materials needed : 
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0 . 75% (w/v) agarose (Indubiose A37, Reactifs IBF, Genne-
villier s) in CFD 
10% (v/v) EA 
1.5% (w/v) joining agar (Seakem, Marine Colloids Div., 
FMC Corp. , Rockland, ME) 
C6 deficient rabbit serum 
fo u r - sided plexiglass box, 19.5 cm. X 8 em. 
l eveling table 
let form. is so l ubilized in distilled water , 100.0 mI . distilled water 
per tablet . 
cells in Alsever ' s solution are washed (X3) in crn and made up t o 20% 
in CFD . Rabbit anti-sheep red cell anti- serum (Gibco Grand Island Bio-
logical Co. , Grand Island, NY or Welleome Reagents Lt d ., Beckenham, 
England), 0.1 ml. anti- serum per 0.5 ml. packed sheep cells , is add-
ed and the cells are stir red at 4 0 C for 20- 30 minutes to allow attach-
ment of the antibody to the cell membr anes. The sensitized cells 'are ' 
then washed with CFD (X3), made u p to 10% with CFD and stored at 4oC. 
(With the anti- serum used in this laboratory, 0.1 ml. anti-serum per 
0 . 5 ml. packed cells always gives a minimal hemolytic dose of 6- 10 , 
as recoIllIllended by Lachmann and Hobart (l978c) . 
the ear into glass tubes. The blood is allowed to clot for 45- 60 min-
utes at room t emperature . After separation from the clot, the serum 
is divided into 1 ml. aliquots and stored at _70o C. 
assumed its characteristic banding pattern according to the protein ' s 
specific pI. The overlay contains all necessary components for lysis 
o f t he sensitized cells except C6. During an incubation per iod , the 
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e6 protein will diffuse up into the agarose overlay and completing the 
cascade, will cause bands of lysis. 
!o~r.!n.8. .2.f_t!!.e_o~e.!.l!9' : The joining agar (1.5% w/v) and agarose 
(0.75% w/v) is completely melted and kept at 56°e . The detecting cells 
(l0% in ern) are kept at 370e. Moments before the gel is finished fo-
cusing, the deficient serum (0 . 5 ml./gel) is quick-thawed at 370e. The 
focused gel is removed from the electrofocusing apparatus and the four-
sided plexiglass box is positioned approximately midway between the 
electrode strips. Using the 1.5% joining agar, the box is joined to 
the gel. 5 . 2 ml. agarose (0 . 75 % w/v) is cooled to 450 C, 0.35 ml. EA 
(l0% in eFD) added and the mixture is swirled to mix thoroughly. e6 
deficient rabbit serum (0 . 5 ml./gel) is added. The mixture is again 
swirled and then poured into the area formed by the box. The overlay 
is spread by shaking the plate and placing it on the leveling table to 
ensure even distribution. (All these steps must be completed within 
a limited amount of time to ensure a clear overlay . If the agarose is 
cooled too long, it will solidify. Also , addition of detecting cells 
into agarose that is too hot will result in cell clumping.) The plate 
is then incubated in a moist chamber at 4°C for 30-45 minutes. Band-
ing is visualized within 15 minutes at room temperature. 
thicker banding than fresh samples but with experience, the homozygous 
C6AA can be easily distinguished from the heterozygous e6AB . Plates 
should be read as soon as the bands are developed. If left too ' long , 
overdeveloped homozygous patterns may be misread as heterozygous e6AB. 
C7 Detection 
Materials needed : 
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0.75% (w/v) agarose (lndubiose A37 , Reactifs lBF, Genne-
villie r s) in EDTA-PBS 
10% (v/v) guinea pig cells in PBS 
1.5% (w/v) joining agar (Seakem, Marine Colloids Div., 
C56 serum 
FMC Corp ., Rockland, ME) 
fo ur - sided plexiglass box, 19.5 cm. X 8 cm . 
leveling table 
is solubilized in distilled water, 100.0 m1. per tablet. 
!DIA..:.P!S_s!.o.£k_s..Q.l.,!!.t.!o,!!. : .A solution of 0.01 M EDTA (Sigma Chemi-
cal Co. , St. Louis, MO), 0.2 M Na 2 ·EDTA (Fisher Scientific Ltd., Whitby, 
ON) and 0.2 H Na4 · EDTA (BDH Chemicals, Toronto, ON) is made in PBS. 
The pH is brought to 7.2 with 1 H NaOH (BDH Chemicals , Toronto, ON) if 
necessary . The stock solution is stored at 4°C and used as 5% in PBS . 
~u.!n~aJ.!g_c.!:.l!s: Cells obtained through heart puncture of healthy, 
normal guinea pig are washed (X3) in PBS and stored at 10% (volume pack-
ed cells/volume in PBS) at 40 C. 
days post-trauma, whether i t be childbirth, surgery or infection (bac-
terial or viral), specific serum proteins are known to increase in 
concentration, mor eso in some individuals than in others (Thompson and 
Rose, 1968; Gamot , 1974; Fust et a!. 1976; Hak , 1978). Complement 
components C5 and C6 are two of these proteins. Blood from such sub-
jects is obtained and serum collec t ed off the clot is treated with 
yeast suspension, as prepared by Lachmann and Hobart (1978c) , (a kind 
gift from Dr. M.J. Hobart). 50 ~ 1. yeast suspension per 1. 0 ml. ~erum, 
overnight at room temperature (see principle below). Centrifugation 
removes the yeast and the serum is aliquoted in 1 ml. volumes and is 
stored thereafter at _700 C. 
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the alternative complement pathway results in consumption of the com-
plement components. If there are elevated l evels of C5 and C6 , there 
will be great amounts of C56 formed as the other components are de-
pleted; C7 is usually at a limiting concentration and is exhausted by 
this treatment . 
Serum deposited into the test plate well diffuses into the agarose 
and any C56 in the test serum will attach to the guinea pig cell mem-
branes . Normal human serum incor porated in the agar ose will supply the 
requir ed C7, C8 and C9 for lysis of the cel ls . Activation of the ear-
lier components in the normal human serum is inhibited by the incorpo-
ration of EDTA in the agarose which chelates the magnesium and calcium 
ions required for ac t ivation o f either pa t hway. Therefore, lysis occurs 
only in the areas where C56 is pr esent. The diameter of the ring is 
indicative of the concentration of C56 i n the test seI:).I,IIl Gaee liguroe IJ). 
Serum giving no or minimal rings of lysis is discarded. No further 
purification is necessary • 
..!.e.!t..!nz. ,2.f _t.!!e_t!.e!!.t.!;.d_ s!:.r.!:!.m_f.2.r _C~_a..£t..!v..!ty : Materials needed 
are as follows: 
2 . 0% agar ose (w/v) (Seakem, Marine Colloids Div., FMC 
Corp . , Rockland , ME) 
10% (v/v) guinea pig cells in PBS 
NHS (normal human serum) 
5 cm . X 5 cm . glass plate , clean 
Completely melted agarose which has been kept at 560 C is cooled 
to 370 C. 0 . 20 ml. NHS and 0 . 20 ml. guinea pig cells (10% v/v') are 
added and after thorough mixing, the mixture is poured onto the clean 
glass plate and spread evenly to all edges . The agarose is allowed to 
harden and wells are punched. 7 1Jl . of test serum is deposited per 
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Figure IX . Test plate for C56 activity in yeast treated acute 
phase sera. Test sera deposited into wells. diffuse into agar 
containing guinea pig cells , EDTA and normal human serum (NHS) . 
EDTA prevents de novo activation of complement. C56 present in 
the test sera attaches to the cell membranes. C7. C8 and C9 
from the NHS complete the cascade and lysis occurs. Wells 5 
and 6 contain sera having high C56 activity, wells I, 2 and 3, 
adequate activity and well 4, inadequate activity. 
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well. The test plate is incubated at 40 C overnight and then placed in 
a 370 C incubator and warmed for 1-2 hours. 
!r.,!.n.£i£.l.!:. £f_t!!.e_CI £v.!:.rlaz: Once focused, the C7 protein is in 
a banded pattern according to the proteins I s pI. C7 rapidly diffuses 
up into the overlay containing guinea pig cells and C56. The presence 
of the EDTA in the overlay inhibits any activation of the classical or 
alternative pathways. C7 complexes with the C56 which has attached to 
the cell membranes and C8 and c9 supplied in the C56 serum complete 
the cascade. Bands of lysis appear in the areas of high C7 concentra-
tion. 
made ready as in the C6 procedure, that is, the agarose for joining and 
overlay are completely melted and kept at 56°C, the detecting cells are 
kept at 37°C and the C56 serum is quick-thawed at 37°C just moments be-
fore the gel is finished focusing. The gel is removed from the appara-
tus and the box positioned about midway between the electrode strips 
and joined to the gel with the joining agar. 5.2 ml. agarose (0.75% w/v 
in EDTA-PBS) is cooled to 37°C. 0.5 ml. C56 serum and 0.35 ml. 10% (v/v 
in PBS) guinea pig cells are added, mixed thoroughly and poured, dis-
tributing evenly within the area formed by the box by shaking the plate 
and then placing it on the leveling table. As with the C6 overlay, 
these steps must be done in a limited amount of time. The plate is 
incubated at 40 C for 15 minutes. 
C6 Results 
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CHAPTER IV RESULTS 
Approximately 2400 sera were typed for C6 by the hemolytic overlay 
technique (see Methods), these being derived mainly from three sources : 
(i) West Coast community study, (ii) Newfoundland families plus random 
individuals and (iii) Labrador myotonic dystrophy family. Details of 
each collection are given in the Materials and Methods section. 
!h~n~ty'p~s_aE.d_all~l~s : The typical pattern observed consisted 
of a ladder-like pattern of 3 to 4 bands of hemolysis (Figure X-A,B,C) 
spreading approximately between pH 6 and pH 8. By comparison with pub-
lished reports, it was obvious that the majority of patterns were de-
rived from two alleles in homozygous or heterozygous forms , a fact 
which was confirmed by family studies (see below). The two alleles 
have been called C6*A and C6*B . 
Several rare phenotypes were observed. Serum H.D., a Newfoundland 
person, used from repeated bleeds as a reference serum, always showed 
a pattern shown in Figure X-D. This is interpreted as an A allele to-
gether with a more acidic variant allele whose lines interdigitate with 
those of C6*A. From descriptions of variants (Hauff et al. 1979), this 
is considered to be a C6*A1 but comparisons with a reference C6*Al have 
not been possible . Fifteen other sera with this same allele were found, 
eleven were together with C6*A and four were C6*Al with C6*B (see Fig-
ure X-E). Another rare pattern, shown in Figure X- F, is interpreted 
as an A allele with a variant B allele; clearly, the bands of th~ va -
riant allele are shifted to a slightly more basic pH and interdigitate 
with those of the common C6*B allele (Figure X-G). It is because of 
this minor shift that this is thought probably to be a rare C6*Bl al-
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lele, as described by Hauff et a1. (1979). Unfortunately, no reference 
serum was available to confirm this . This C6*Bl allele was observed 
in six sera, only in combination with C6*A. A study of a single South 
African family fortuitously revealed the rare pattern shown in Figure 
X-H. This is considered to be a B allele together with a variant of 
neither the A or B allele since the lines interdigitate with both those 
of C6*A and C6*B. This is compatible with the allele described by 
Mauff et a1. (1979) which was designated C6*M. This rare allele was 
observed in a nephew of the man just described but was in combination 
with C6*A (see Figure X-I). 
The phenotype and actual numbers observed in each collection stu-
died are given in Table VI. 
h.lle!e_f.!..e.9.u~n.£i~s_a!!.d_i!!.h~r..!.t.!!.n.£e..:.. Although the West Coast com-
munity is known to contain many related individuals , all results were 
pooled as random samples for the calculation of the allele frequencies. 
In the Newfoundland families plus random individuals collection any 
known related persons were collected into family units and only the al-
leles from the parents or founders were used in the counting, all other 
samples were treated as random. The South African family was not in-
cluded in the calculations. The Labrador collection of 110 individuals 
is an extended family and therefore allele frequencies were not calcu-
lated. The allele frequencies for the West Coast community and the 
Newfoundland families plus random individuals are given in Table VII. 
It can be seen that there is no significant difference between ~he 
allele frequencies of these two populations and those previously stu-
died. 
Single parent-offspring combinations, as well as mating pair - off -
Tabl e VI. Observed phenotypes in three Newfoundland popul ations. 
Collection 
West Coast community 1075 Observed 
EX2ected 
X' 
Newfoundland families 
plus random individuals 689.5 Observed 
Labrador myotonic 
dystrophy family 
Expected 
X' 
llO Observed 
AA AB BB 
418 522 133 
429.5 498.8 144.8 
0 . 3079 1.0791 0.9616 
35 1 249 79 . 5 
332 . 8 285.5 61.2 
0 . 9953 4.6664 5.472 1 
73 36 
ABI AlB 
I I 
0.3 0 . 2 
1. 6333 3.2 
2 3 
0.7 1.2 
2.4 143 2.7 
AlA 
5 
, 
~ 
2.8 ~ , 
1. 7286 
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Figure X. C6 phenotypes observed in Newfoundland. Track A = C6M. track B = C6BB. 
track C :: C6AB, track 0 :: C6AIA, track E :: C6AIB, track F :: C6ABl, track G :: C6BB. 
track H :: C6BM. track I :: C6AM. 
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pring combinations. 10Iere observed in all three collections (see Ta bles 
VIII, IX. x. XI). No unusual combinations were observed. There was 
no evidence of selection against the inheritance of rare alleles. Mat-
ing pair frequencies, calculated only for the West Coast community 
(Table IX) and the Newfoundland families (Table X). revealed no signi-
Hcant deviation from the expected mating frequencies . 
.t1e!!.d~l!a.!!. Ea!.iE.s : Actual and predicted numbers o f progeny from 
the matings observed in the three collections are shown in Tables IX, 
X and XI. Of significance is the excess of C6AA and deficit of C6AB 
offspring resulting from C6AB X C6AB matings in the Newfoundland fami-
lies collection. However, in all o ther instances, there is no signi-
ficant deviation between the expected and observed offspring number 
resulting from the various mating pairs. 
evidence of C6 linkage with the HLA complex. Since all were t1ol0 gene -
ration families, zl scores (and e 1 scores where necessary) were calcu-
lated as shown by Alan E. H. Emery in Methodology in Medical Genetics . 
~. For those families with sibships larger than seven, lod scores 
were calculated as suggested by R.R. Race and R. Sanger in Blood Groups 
in Man. 1975. Combined lad scores for 19 males and 7 females gave ne-
gative values for all recombination fractions , as shown in Table XII. 
cOllUDunity revealed the increased incidence of a variant of red cell 
superoxide dismutase (SOD). The pedigree is given in Figure ~I. Sera 
were available for 23 family members and were typed for C6 . Unfortu-
nately, the C6 results were uninformative and therefore an attempt to 
statistically link this SOD locus with that of C6 was not possible. 
Table VIII. Single parent-offspring combinations. 
Parental Collection Offspring Genotype 
Genotn~e AA AB BB ABI 
AA West Coast community 44 77 35 112 
Newfoundland families 17 32 7 39 , 
Labrador M.D. family 3 1 5 6 ~ 
0 , 
AB West Coast community 61 39 71 31 142 
Newfoundland families 32 49 50 15 114 
Labrador M.D. family 1 2 0 3 
BB West Coast community 16 18 27 
Newfoundland families 4 7 8 
Total single parents 178 Total offspring 451 
Mating Pair 
AA x AA 
AA x AB 
AA x BB 
ABxAB 
AB x BB 
BB x BB 
AlB x AA 
Table IX. Observed mating pairs and inheritance of C6 alleles 
in the West Coast community. 
n X' Offspring Genotype 
OBS~EXP2 AA AB BB 
16(20.8) 1.1077 61(61) 0(0) 0(0) 
55(48.4) 0.9 75(85.5) 96(85.5) 0(0) 
5(14.0) 4.5714 0(0) 20(20.0) 0(0) 
33(28.1) 0.8544 23(24.0) 53 (48.0) 20(24.0) 
16(16.3) 0.0055 0(0) 30(27 .5) 25(27 .5) 
4(2.4) 1.0667 0(0) 0(0) 7(7.0) 
Total msting 
pairs 130 Total offspring 
Ix2mating ,., 8.5057, insignificant at P > 0.05, df .. 5. 
X' 
61 
2.578 171 
20 
1.230 96 
1.684 55 , 
7 ~ 
, 
411 
Table X. Observed mating pairs and inheritance of C6 alleles 
in Newfoundland families. 
Mating pair X' Offspring Genotype X' 
OBS~EXP2 AA AB BB 
AAxAA 13(18 . 2) 1.4B57 36(36) 0(0) 0(0) 36 
AA x AS 25(31.2) 1.2321 61(54.5) 48(54.5) 0(0) 1.5504 109 
AA x BB 4(6.7) 1.00Bl 0(0) 8(8 . 0) 0(0) 8 
AB x AB 20(13.4) 3.2507 33(18.5) 21(37.0) 20(18.5) IB.4095 74 
AB x BB 9(5.7) 1 .9106 0(0) 15(15.0) 15(15.0) 0.0 30 
BB x BB 1(0.6) 0 . 2667 0(0) 0(0) 5(5 . 0) 5 
Offspring Genotype 
AA AB AlA AlB ABI , ~ 
AA x AlA 0(0.5) 0(0) 1(0.5) 0(0) 0(0) 0.5 
, 
AA x AlB 0(0) 1(1.5) 2(1.5) 0(0) 0(0) 0.3334 
AA x ABI 1(2) 0(0) 0(0) 0(0) 3(2) 1.0 
AS x AlA 6(2.5) 1(2.5) 3(2.5) 0(2 . 5) 0(0) 5.9 10 
Total mating 
pairs 78 Total offspring 280 
L X2mating ,., 9.2339. insignificant at P > 0.05 , df - 5. 
Mating Pair 
AAxAA 
AAxAB 
AB x AB 
Table XI. Observed mating pairs and inheritance of C6 alleles 
in a Labrador myotonic dystrophy family. 
Offspring Genotype 
AA AB BB 
26(26 . 0) 0(0) 0(0) 
17(16.0) 15(16.0) 0(0) 
2(1.0) 2(2 . 0) 0(1.0) 
Total mating pairs 11 Total offspring 
X' 
0.135 
1.0 
26 
32 
62 
, 
~ 
w , 
Table XII. C6 - HLA linkage study. 
Sex of Two generation families; lad score at recombination fraction 9: , ~ 
Heterozxgote 0.01 0.05 0.10 0.15 0 . 20 0.25 0.30 0.35 0.40 0 . 45 ~ , 
Male 19 - 39.98 -18.65 -10.37 -6.13 -3 . 60 -2.01 - 1 . 02 - 0 . 45 - 0 . 15 - 0.03 
Female 7 - 23 . 30 -11. 78 - 7.13 - 5.17 -3.04 1. 94 1. 16 -0.54 -0.21 - 0.07 
Combined 26 63.28 30.43 -17. 50 -11. 30 - 6.64 -3.95 2.18 0.99 - 0.36 - 0 .1 0 
4495 3509 3279 3634 2077 1214 
C6AB C6AB C6AB C6AB C6AA 
3618 1071 1350 
C6AA C6AA C6AA 
'Figure XI. Pedigree for the C6 - SOD linkage attempt. Filled in figures 
represent individuals typed as heterozygous for the SOD variant, crossed 
figures are inferred heterozygous. C6 results are given . 
(used with permission of Ms. S.K. Buehler) 
, 
~ 
~ , 
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C7 Results 
All sera typed for C6 were typed. again by the hemolytic overlay 
technique (see Methods). for C7. 
~h!.n~typ!.s_a.!!.d_a!l!.l!.s: The typical pattern observed consisted 
of 4 bands of hemolysis that stretched in ladder-like fashion from 
approximately pH 5 to pH 7 (see Figure XII-AB). Comparison with pub-
lished data (Hobart et a1. 1978) indicated that this pattern is derived 
from the C7*1 allele. 
Only three rare phenotypes were observed. Serum T.N., a Chinese 
medical student at Memorial University of Newfoundland , revealed the 
pattern shown in Figure XII-D . This individual was re-bled and the 
pattern was unchanged . This is interpreted as a C7*1 allele with a va-
riant whose bands are of equal intensity to those of C7*1. This variant 
pattern is considered to be due to the C7*2 allele and was confirmed by 
running next to a reference sample kindly provided by Dr. M.J. Hobart. 
This C7 2-1 pattern (Figure XII-F) was also demonstrated in the serum 
of the brother of T . N., D.N . , who is a student in the Faculty of Engi-
neering at Memorial University, and in an related individual, L.H ., 
who is also of Asian descent . Tvo sera, S . J. (Figure XII- G) and T.J. 
(Figure XII-E), found independently in the supposedly random collection. 
demonstrated another rare phenotype . A fresh sample of S.J. was ob-
tained and rerun, showing no change in the pattern which is interpreted 
as a C7*1 allele with a variant whose bands appear at a more acidic pH 
than those of C7* 1 or C7*2 and are seeminly of weaker intensity'. It is 
believed that this allele is the C7*3 described by Hobart et a1. (1978). 
Noting that the two individuals shared the same surname, it was possi-
ble to trace and establish their relationship as brothers from the 
'+' 
. ABCDEFO . ABCDEFO •..••...... _._ .. -
Figure XII. C7 phenotypes observed in Newfoundland . Tracks A and B = C7*1. track 
C = C7*3 , tracks 0 and F = C7 2-1, tracks E and G = C7 3- 1 (shown in duplicate). 
~ 
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Eagle River area of Labrador. A single individual, M.M .• a 29 year old 
female from Goose Bay, Labrador, was hospitalized here at the Health 
Sciences Centre, St. John's. Newfoundland, for surgery to repair a torn 
meniscus and luckily was available for rebleeding. Confirmation of the 
pattern shown in Figure XII-C was possible. The pattern is believed to 
be due to either C7*3 homozygosity or else the C7*3 allele is in combina-
tion with a null allele as C7 3-0. Through M.M. '. kind cooperation and 
her own keen interest in her ancestry, a 4 generation pedigree for her 
family was obtained, with some detail as to the origin of each branch 
in the first generation (see Figure XIII). Of particular interest is 
the ancestor of individual 1-2, a Norvegian who had the same unusual 
given name as the Eagle River individual, T.J .. The use of family 
'$8mes is custo!Mry in the communities of Labrador and Newfoundland and 
with such a distinctive given name, typical only in Scandinavian coun-
tries, it is highly probable that the three individuals demonstrating 
the C7*3 allele are descended in some manner from this common ancestor 
or his spouse. This family is to be investigated further. but this is 
ou side the time frame of this thesis. 
C7 Typing Problems - Due to an Aging Artifact? 
During attempts to produce C7 allotyping data for the West Coast 
community, a variation in pattern in some sera was discovered which 
appeared to be a heterozygote patten. The extra band occurred at 
approximately the position that published data showed was occupied by 
a C7*3 allele. Since the West Coast community had been visited .for 
blood collection in 1974, 1975. 1976 and 1979, it was possible to 
confirm this pattern on three different bleeds from the same indivi-
dual. On retyping, it was found that the variant pattern was not al -
II 
III 
IV 
4 
e7 1 
10 11 
e7 1 
Figure XlII . Labrador family having a C7 *3 phenotype (individual III-2).. Ancestors for 
each branch of the first generation are as follows: I - I. Isle of Barra, 
Scotland; 1-2 , Norway; 1 - 3, Liverpool, England and 1-4. England. 
Individuals 1-4. II-lO and IU-2 have been C7 typed. 
, 
~ 
~ , 
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ways present and was sometimes barely visible (Figure XIV). Further-
more, when many sera collected in 1974 were examined, all showed this 
supposedly "heterozygote" pattern. It was therefore thought likely 
that the pattern was due to aging of the sera. To test this idea, se-
veral experimen ts were undertaken as follows: 
sera from twelve healthy laboratory workers were frozen at -700C, thaw-
ed at 370C and immediately refrozen at -700C on five successive days. 
After this treatment, all still showed the typical C7 1 pattern. 
gle healthy laboratory worker was left in a capped test tube at room 
temperature for 24 hours and then typed for C7. The typical C7 1 pat-
tern was observed . This same serum (now 24 hours old) was frozen at 
-700C, then thawed at 37°C and put into a petri dish to increase the 
surface area . Retyping after anothe r 24 hours still showed the typical 
C7 1 pattern. 
thy student was heat inactivated at 560C for one half hour. Subsequent 
typing showed no apparent change in the C7 1 pattern. 
Thirty-one sera which had been stored at -200C for 2 to 9 years were 
typed for C7. All samples contained banding in the positions for al-
leles C7 1 and C7 3 . The intensity of the C7 3 positioned bands increased 
with increasing serum age (see Figure XV) . 
from healthy factory workers in China by Dr. S. N. Huang, were carried 
at room temperature back to Newfoundland and stored thereafter at 40c. 
'+' 
HAReN 2.2. /;'1 ,.. .... 
Figure XIV. Progressive appearance of C7*3 positioned artifacts in the West Coast. 
sera . For each serum number shown, samples from 1974 . 1976 and 1979 have been C7 
a 11 otyped ; n tracks above (A '" 1974. B = 1976. C '" 1979 for serum 1119; 0 = 1974, 
E = 1976. F = 1979 for serum 1126; etc.). 
;:: 
fB 
("1"R. 26 .g. A 
~;;i~~~~~;~;~~;~ 
Figure XV. C7 patterns of sera stored at -20oC for 2-7 years. Tracks A- P contain 
sera stored at -200C since date indicated . Tracks Q and R contain control C72-l. 
Intensity of the artifact bands {noted by arrow} increases with i ncreasing serum 
age. 
;;j 
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Typing of 20 of these sera showed patterns unlike any C7 pattern seen 
before and comparison with CaucBsian sera kept at 40 C for one year was 
not possible. Some signs of underlying polymorphism were noted in the 
Chinese sera. Five of the 20 samples (Figure XVI-A,C,L ,N,P) show the 
C7 1t 2 pattern found in the heterozygous sample T . N. (Figure XVI-J). 
for this alteration , by causing V -sUlfide bond breakage , it was de-
cided to try to reverse it with reducing agents. Serum which had been 
stored since 1978 at _200 C and showing a "heterozygote" pattern was 
treated with a small amount of dithiotreitol which caused total dis-
ruption of serum proteins. No C7 pattern was observed. A second serum 
was treated in a 3:1 ratio with 0.2 M mercaptoethanol and was immedi-
ately typed for C7. No change was seen in the " heterozygote" pattern. 
A third serum was treated with an equal volume of mercaptoethanol for 
various time periods . Disruption of all serum proteins occurred in 
samples treated for more than 8 minutes. Those treated with the reduc-
ing reagent for less than 8 minutes showed no disappearance of the sup-
posed C7 *3 bands . 
f.o.!lclu~i2.n: It seems certain that aging of frozen sera, either 
at _200 C or at _700 C for more than one year , produces an artifactual 
change in the serum such that it types for C7 as C7 3-1 , with a very 
weak C7 *3 line initially which gets· stronger with longer storage. It 
o • 
is probable that storage at 4 C for a year allows further changes to 
occur such that a complex multi-lined pattern appears. · "No- physico-
chemical basis for these changes is yet apparent. 
~" ~'1 ~ "),:.. r -7 
. A • C D E F O' H I ' J K L III N 0 P Q R 5 T 
••••••••••••••••••••• 
Figure XVI. C7 patterns observed in aged Chinese sera . Track J contains control C72-l. 
*2 band ; s noted by the arrow. Al though there ; s extens; ve a rti factua 1 bandi ng. C7*2 
bands are thought to exist in sera of tracks A, C, L, N, P. 
~ 
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CHAPTER V DISCUSSION 
The Genetics of Human C6 
~l!e!e_f!.esu.£.n£.i.£.s: The frequencies for the common alleles, C6*A 
and C6*B, found in the present study are similar to those found in 
other populations previously studied as reviewed in Chapter 1. The 
West Coast community includes a large number of related individuals, 
85% of the population being genealogically traced back to a single an-
cestral pair, yet, the C6*A (0.6321) and C6*B (0.3670) frequencies are 
no t significantly different from those found in the rest of the New-
foundland population in which all known related members were collected 
into family units before calculation of the allele frequencies, C6*A 
(0.6947) and C6*B (0 . 2980). This is probably due to two factors, the 
first of which is that this is basically a two allele balanced poly-
morphism and secondly, the number of founders in the second and third 
generations was quite large . 
Rare alleles C6*Al and C6*Bl occurred infrequently in the West 
Coast community study, having a combined frequency of 0.001 and no 
family data were obtained to show that these alleles were inheritable. 
The Newfoundland families plus random individuals collection had a 
slightly larger combined frequency (0 . 0073) of rare alleles, the C6*Al 
(frequency" 0.0058) occurring more frequently than C6*Bl (frequency · 
0 . 0015) . These rare patterns were shown to be consistant with Mendel-
ian inheritance of a rare allele by family study and there was no evi-
dence of selection (unfavourable transmission ratio) against them. 
An excess of C6BB homozygotes and a deficit of C6AB heterozygotes 
were noted in the Newfoundland families plus random individuals collec-
tion. Examining the sub-populations of this collection, the excess 
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could be attributed primarily to the C6 phenotypes of the random indi-
viduals. Considering the possibility of technical error, it was thought 
that any bias 'WOuld slant toward the misreading of a C6AB as a homozy-
gous C6BB (possibly caused by protein overload or overdevelopment of 
the plates before reading, see Methods). Therefore, the random indivi-
duals previously typed as C6BB were re-typed . The correction changed 
the prior calculations minimally. Therefore, this deviation of observed 
from expected phenotypes is thought probably due to chance. 
In!!e.!.i!.a.!!.c~ £f_C~ ~l.!.e!e.!: An initial study of the segregation 
of C6 alleles (Hobart et a1. 1977) noted a slight increase in the num-
ber of C6AB progeny from C6AB X C6AB mating. Since there is evidence 
of duplication of the C6 locus in dogs (Hobart. personal communication) 
and of the C4 locus in humans (O'Neill et a1. 1978a; O'Neill et a1. 19-
78b); this asymmetry of Mendelian ratios suggested the possibility of 
duplication at the C6 locus (Hobart, personal communication). Collec-
tion of further data on this topic was of interest in this study. Mat-
Ings of heterozygotes in the West Coast community and the Labrador myo-
tonic dystrophy families gave results which were compatible with regular 
Mendelian inheritance at a single locus. Parent combinations other 
than C6AB X C6AB in the Newfoundland families revealed no significant 
deviation of the observed and expected offspring frequencies. However, 
C6AB X C6AB matings gave an excess of C6AA offspring. This is the op-
posite finding to that of Hobart et a1. (1977) and does not support the 
idea of duplication of the C6 locus. The excess of C6AB chilaren noted 
in the first study (Hobart et al. 1977) can be given two possible ex-
planations. It may have been due to chance but may also have resulted 
from a storage effect. Older serum has a tendency to be more difficult 
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to allotype, the banding less crisp~ generally thickened in all posi-
tions (see Allotyping of "older" serum. Methods); this results in 
difficulty in distinguishing C6AA homozygotes from C6AB heterozygotes. 
The storage effect would presumably not result in an excess of homo-
zygote offspring and therefore it is probable that the excess found in 
the Newfoundland families study was due to chance. Taking the resul ts 
together, there is no reason to suggest a more complicated genetics 
than one locus. 
No abnormal phenotypes were evident in any matings which would 
indicate the presence of a null allele. 
!:.iE.~~ ~t.!:!.d.!e~ .!:!.i!.h_C.§.: Data compiled in this thesis for testing 
for linkage between the C6 locus and the lfi.A complex reiterated previ-
ous efforts in that, at no recombination f r action was there a positive 
value. Although the attempt to link the C6 and SOD loci was uninfor-
mative, the C6 data of this thesis is to be used in a major effort to 
link a susceptibility gene for Hodgkin ' s disease and acquired immuno-
deficiency thought to be in the West Coast community , with various mar-
kers (E.A. Thompson, 1980) and in other genetic investigations of di -
sease ongoing in this laboratory (see Samples, Materials). 
The Genetics of Human C7 
Data in this thesis reveal the perplexing presence of an artifact, 
in sera stored for prolonged periods, which mimics a C7*3 pattern. More-
over, the gradual appearance of the artifact may suggest the presence 
of an allele with reduced function . This artifact problem has' not been 
noted by previous investigators. To suggest that a true C7*3 allele may 
therefore not exist would be at the very least hasty and in fact, the 
opposite is suggested; three sera studied in this thesis appear to have 
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alleles, whose products migrate to the C7 3 position. The heterozygote 
pattern. C7 3 • 1 observed in two samples from the supposedly random 
individuals collection, was confirmed on a fresh sample available 
from one of them. Upon further investigation. it was discovered that 
the two individuals were brothers and therefore it appears that they 
share a genuine C7 3 allele . Similarly. the patient who only had a C7 3 
pattern, due to either C7 3 homozygosi ty or to the C7 3 allele in com-
bination with a null allele. was reb led and an identical pattern was 
obtained on typing performed immediately. It happens that these C7 3 
patterns all appeared to have somewhat reduced activity when compared 
with bands of the C7 l or C7 2 alleles, but this reduction is slight. 
Of the nine C7 3 allele patterns described by Hobart et a1. (1978), five 
were also confirmed on fresh sera, three were not able to be traced, 
and one was not confirmed on fresh serum. This single non-confirmation 
might be explained by the presence of arti-i<!-ctual banding . Thus , it 
appears that there are genuine C7 3 alleles which code for proteins having 
somewhat weaker activity than those of the C7 l or C7 2 alleles; 
as well there is an age artifact band resembling C7 3 whose intensity may 
vary from very weak to fully developed . 
The nature of this artifact is unclear and it 1s not known whether 
factors other than storage and age may cause changes in the C7 l protein 
such that its migration mimics that of C7 3 . As was seen in the Chinese 
sera examined. there is a possibility of further aging. resulting in 
other artifactual patterns which are still detectable by the h¥molytic 
method. Therefore, it would seem that sera being examined for C7 poly-
morphism should not have been stored for prolonged periods and all C7 3 
allele patterns observed should ideall y be confirmed on fresh sera. 
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The fact that the e7 2,1 patterns described in this thesis were 
found in Asian persons raised suspicions that the e7 2 allele might 
occur with a greater frequency in Asian populations than in Caucasian 
populations. Although the Chinese sera from mainland China revealed 
some banding thought due to aging, a distinct band 1n the e7 2 pOSition 
in approximately 40% of the individuals allotyped strongly suggests 
that the e7 2 allele frequency is indeed increased. Confirmation on 
fresh samples from a Chinese connnunity is required, (and 1s currently 
underway). but it would appear a e7 2 allele of Chinese origin may have 
reached balanced polymorphism due to some selective pressure 1n the 
Asian environment. 
The major difficulty in confirming linkage of the C6 and C7 loci 
lies i n the fact that in Caucasian populations variation in C7 is rare. 
If these preliminary observations in Chinese are confirmed, then study 
of Chinese families could quickly add a great deal more data for mea-
suring recombination between C6 and C7. 
The identification and availability of the Labrador family des-
cribed in this thesis as having a genuine C7 3 allele may also provide 
information for C6/C7 linkage studies and is to be pursued in the next 
few months. 
In conclusion , the results on C6 and C7 compiled for this thesis 
not only represent the first Canadian data, but also provide the basic 
information for future efforts in this laboratory to map the C6 locus 
by classical linkage methods. In addition , the results on Chinese sera 
and on a Labrador family offer two avenues by which the linkage of the 
C6 and C7 loci may be confirmed and the distance between them estimated 
by recombination. Finally, the identification of artifactual banding 
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tifactual banding of C7 may clarify confusing results that might be ob-
tained by future investigators. 
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APPENDIX 
West Coast community r esults, pages 99- 120 . 
Newfoundland families plus random individuals results, pages 121-144 . 
Labrador myotonic dystrophy family results , pages 145-147. 
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West Coast Communitl Studr Results 
Number c6 Genotype Number C6 GenotYE:e 
1001 AB 1039 AA 
1004 AB 1040 AA 
1006 AA 1041 AB 
1008 AA 1042 BB 
1009 AB 1043 AB 
1010 AB 1044 BB 
1011 AA 1045 AB 
1012 AB 1046 AA 
1013 AA 1047 AB 
1014 AA 1049 AA 
1015 AA 1051 AB 
1016 AB 1052 AA 
1018 AA 1053 AA 
1020 AA 1054 AB 
1021 AA 1055 AB 
1022 AA 1056 BB 
1023 AA 1057 AB 
1029 AA 1058 AA 
1030 AA 1059 AA 
1033 AB 1060 AB 
1034 AB 1062 AB 
1035 AB 1063 AA 
1036 AB 1064 AA 
1037 AB 1065 AB 
1038 AA 1066 AA 
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West Coast Communitr Studr Results 
_ Number C6 Genotrpe Number c6 Genotrre 
1067 AB 1099 AB 
1068 AB 1100 AA 
1069 AB 1101 AB 
1070 AB 1102 AA 
1071 AA 1103 AB 
1072 AB 1105 AB 
1077 AA 1106 AB 
1078 AA 1112 AB 
1079 AA 1116 AB 
1080 AA 1117 AB 
1081 AA 1118 AA 
1082 AB 1119 AB 
1083 AA 1123 BB 
1084 AA 1124 AB 
1085 AA 1125 BB 
1086 AB 1126 AA 
1087 AB 1127 BB 
1088 AB 1129 BB 
1092 AB 1130 AB 
1093 AB 1131 AB 
1094 AB 1132 AB 
1095 AB 1133 AA 
1096 AB 1134 AB 
1097 BB 1135 BB 
1098 AB 1136 AB 
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West Coast Conununiti' Studl Results 
Number C6 Genotype Number C6 Genotne 
1137 AA 1166 AA 
1138 AA 1167 AB 
1139 AB 1168 AB 
1141 AB 1169 AA 
1142 AB 1170 AA 
1143 BB 1171 AB 
1144 AA 1172 AA 
1145 AB 1175 AB 
1146 AA 1177 AA 
1147 AA 1178 AA 
1148 AA 1179 AB 
1149 AB 1180 AB 
1150 AA 1183 AB 
1151 AA 1185 AA 
1152 AB 1186 AB 
1153 AB 1187 AB 
1155 AA 1188 AB 
1157 BB 1191 BB 
1159 AA 1199 AB 
1160 AB 1201 AB 
1161 AA 1202 AA 
1162 AA 1204 AA 
1163 AA 1205 AB 
1164 BB 1206 AB 
1165 AB 1207 AA 
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West Coast Communit~ Stud::! Results 
Number C6 Genotype Number C6 Genotne 
1208 AA 1247 AB 
1209 AA 1248 AB 
1210 AA 1250 AA 
1212 AA 1251 BB 
1213 BB 1253 BB 
1217 AA 1254 AA 
1218 AA 1255 AA 
1220 AA 1256 AA 
1221 AB 1257 AA 
1222 AA 1258 AA 
1223 AB 1259 AA 
1225 AA 1343 AB 
1226 AB 1344 AA 
1229 AA 1345 AA 
1230 AA 1346 AA 
1233 AB 1347 AA 
1235 AA 1348 AA 
1237 AB 1349 AA 
1238 AA 1350 AA 
1239 AA 1351 AA 
1240 AA 1503 AB 
1241 AA 2001 AB 
1242 AA 2002 AA 
1243 AA 2003 AA 
1245 AB 2004 AB 
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West Coast Coonnunitr Studr Results 
Number c6 Genotrpe Number C6 Genotrpe 
2005 AB 2036 AA 
2006 BB 2037 AA 
2007 BB 2039 AA 
2008 AB 2040 AB 
2009 AA 2041 AB 
2010 AB 2044 AB 
2012 AA 2045 AB 
2013 AA 2046 AB 
2014 BB 2047 AB 
2015 BB 2048 AB 
2016 AB 2049 AB 
2017 AB 2053 AA 
2018 AB 2054 AB 
2019 AA 2055 AB 
2020 AB 2058 AA 
2021 AB 2060 AA 
2022 AB 2061 AA 
2025 AB 2063 AA 
2029 AB 2064 BB 
2030 AB 20';6 AA 
2031 AA 2067 AA 
2032 AB 2068 AA 
2033 AA 2069 AB 
2034 AA 2070 AB 
2035 AB 2071 AlB 
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West Coast Communit;t Stud:t Results 
Number C6 Genot;tPe Number c6 Genot:tEe 
2072 BB 2102 AB 
2073 BB 2103 AB 
2074 BB 2104 AB 
2075 AB 2105 AB 
2076 AA 2107 AA 
2077 AA 2108 AB 
2078 AA 2 109 AB 
2080 AA 2111 AA 
2081 AB 2112 AB 
2082 AA 2114 AA 
2084 AA 2115 AA 
2085 AA 2194 AA 
2086 AA 2196 AA 
2087 AB 2197 AA 
2088 AA 2199 AB 
2089 AA 3001 AB 
2090 AA 3004 AA 
2091 AB 3006 AB 
2092 AB 3007 AA 
2093 AB 3009 AA 
2094 AA 3010 AB 
2096 AA 3011 AB 
2097 AB 3012 AB 
2100 AB 3013 AB 
2101 AB 3015 AA 
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West Coast Conununiti': Studi': Results 
Number c6 Genoti':pe Number c6 Genoti':pe 
3016 AA 3054 AB 
3017 BB 3055 BB 
3018 AB 3056 BB 
3019 BB 3057 AB 
3020 AB 3058 AB 
3021 AB 3060 AB 
3023 AA 3061 AB 
3026 AA 3063 AB 
3027 AA 3064 BB 
3029 AA 3065 AB 
3031 AA 3066 AB 
3032 AA 3067 AA 
3034 AA 3068 AB 
3035 AA 3069 AB 
3038 AB 3072 AB 
3039 AB 3073 AB 
3040 AB 3074 AA 
3042 AB 3075 BB 
3043 AB 3076 BB 
3045 AA 3078 AB 
3046 AB 3080 AB 
3047 AB 3081 AB 
3048 AB 3082 AB 
3049 AA 3083 AB 
3050 AB 3084 AB 
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West Coast Communitr Stud:t Results 
Number C6 Genotype Number C6 Genoqpe 
3086 AB 3127 BB 
3088 AA 3128 AB 
3090 AA 3129 AA 
3091 AB 3130 AA 
3092 AB 3133 BB 
3093 BB 3135 AA 
3095 AB 3143 AB 
3096 AB 3146 AB 
3099 BB 3148 BB 
3101 BB 3149 AB 
3102 AB 3150 AA 
3103 AB 3151 AB 
3104 AB 3152 BB 
3105 AB 3153 BB 
3106 BB 3155 AB 
3112 AB 3157 AB 
3114 AA 3158 AB 
3115 BB 3159 BB 
3116 AB 3162 AA 
3117 BB 3163 AA 
3120 AA 3164 AB 
3122 AB 3165 AA 
3124 AB 3166 AB 
3125 AB 3169 AB 
3126 AB 3170 AA 
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West Coast Communit:t: Studr Results 
Number C6 Genotrpc Numb~ C6 Genotrpe 
3171 AA 3208 AB 
3172 AA 3209 BB 
3173 AB 3210 AB 
3175 AB 3212 AB 
3176 AB 3213 AB 
3177 BB 3214 AB 
3178 BB 3215 AA 
3179 AB 3219 AA 
3180 AB 3220 BB 
3181 AA 3221 BB 
3183 AB 3222 AA 
3186 AB 3223 AA 
3188 AA 3224 AB 
3189 AA 3226 AA 
3190 AB 3227 AA 
319 1 AB 3228 AB 
3194 AA 3229 AA 
3195 AA 3230 AA 
3197 AA 3231 AB 
3199 AA 3232 AB 
3202 AA 3233 BB 
3203 AB 3234 AB 
3204 AA 3235 AB 
3205 AB 3236 AB 
3206 AB 3237 AB 
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West Coast Conununitl Studl Results 
Number C6 Geno,tlpe Number C6 Genot:tPe 
3238 AS 3275 AS 
3244 AB 3276 AA 
3246 AA 3279 AB 
3247 AA 3280 BB 
3250 AB 3281 AB 
3251 AA 3286 AB 
3252 BB 3287 AA 
3255 AB 3288 AA 
3256 BB 3289 AB 
3257 AA 3294 AB 
3258 BB 3296 AB 
3259 BB 3297 AB 
3260 AB 3298 AA 
3261 BB 3300 AA 
3262 AB 3301 AB 
3263 AB 3302 BB 
3265 AB 3304 AB 
3266 AB 3306 BB 
3267 AB 3308 AA 
3269 BB 3310 AS 
3270 BB 3312 BB 
3271 AA 3316 AS 
3272 AS 3317 AB 
3273 AS 3319 AA 
3274 AB 3321 AA 
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West Coast Communit:z: Studr Results 
Number c6 Genot:z:pe Number c6 Genot:z:pe 
3322 AA 3365 AB 
3325 AA 3367 AA 
3327 AA 3369 AB 
3329 AA 3370 AB 
3330 AA 3371 AB 
3332 AB 3372 AB 
3335 AA 3373 AB 
3336 BB 3374 AA 
3337 BB 3375 BB 
3340 AB 3377 BB 
3342 AB 3378 BB 
3344 AB 3379 BB 
3347 AB 3384 AA 
3348 AB 3385 AA 
3349 AA 3386 AB 
3352 AA 3387 AA 
3354 AA 3388 AB 
3355 AA 3389 BB 
3356 AA 3390 AA 
3359 AA 3392 AA 
3360 AA 3395 AB 
3361 AA 3396 AA 
3362 AB 3397 AB 
3363 AB 3398 AA 
3364 AB 3399 AA 
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West Coast Communitr Studr Results 
Number C6 Genotrpe Number C6 Genotype 
3400 AA 3436 BB 
3401 AA 3437 AA 
3402 AS 3438 AB 
3403 BB 3439 AS 
3404 AB 3441 BB 
3405 AB 3442 BB 
3406 AA 3443 BB 
3407 AA 3444 AB 
3409 BB 3445 AA 
3410 AB 3446 AS 
34 12 AB 3448 AS 
34 14 AB 3449 AA 
34 16 BB 3451 AS 
3417 AS 3452 AA 
34 18 AB 3453 AA 
3420 BB 3454 AS 
3421 AA 3456 AS 
3425 AS 3457 AS 
3427 BB 3458 AS 
3429 AA 3460 AS 
3430 AS 3461 AA 
3431 AS 3462 AA 
3433 BB 3463 AS 
3434 BB 3464 AS 
3435 BB 3465 AB 
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West Coast Comrnunit:z: Stud:t Results 
Number C6 Genot:z:pe Number C6 Genot:z:pe 
3466 AA 3498 AA 
3468 AB 3499 AB 
3469 AB 3500 AB 
3471 AA 3501 AA 
3472 AB 3505 AB 
3473 AA 3506 AA 
3475 AA 3509 AB 
3476 AA 3510 AB 
3477 AA 3511 AB 
3478 AA 3512 AA 
3479 AB 3514 AA 
3480 AB 3516 AB 
3481 AB 3517 AB 
3482 BB 3518 AB 
3483 AB 3519 AB 
3485 BB 3520 AB 
3486 AB 3522 AB 
3487 AA 3527 AA 
3489 AB 3528 AB 
3490 AB 3529 AB 
3491 AB 3530 AB 
3492 AA 3531 AB 
3495 AB 3532 AB 
3496 AB 3533 AA 
3497 AA 3534 AB 
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West Coast Communitr Stud): Results 
Number C6 Genotrpe Number C6 Cenotrpe 
3535 AB 3567 AB 
3536 AB 3568 AA 
3537 AB 3569 AB 
3538 AB 3570 AA 
3539 BB 3571 AA 
3540 AB 3572 AB 
3543 AA 3573 AB 
3545 AA 3575 BB 
3546 AA 3577 AB 
3547 AA 3580 AB 
3548 AB 3581 AB 
3550 BB 3582 AA 
3553 AB 3583 AA 
3554 AB 3584 AB 
3555 AA 3585 AA 
3556 AA 3587 AA 
3557 AA 3588 AB 
3559 BB 3589 AB 
3560 AB 3590 AA 
3561 AA 3591 AB 
3562 AA 3592 AA 
3563 AA 3593 AB 
3564 AB 3594 AB 
3565 AB 3595 AB 
3566 AB 3596 AA 
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West Coast Communitr Studr Results 
Number C6 Genotype Number C6 Genotype 
3597 AB 3659 AA 
3598 AA 3663 AB 
3599 AA 3664 AB 
3601 AB 3667 AA 
3605 AA 3668 AA 
3606 AA 3669 AB 
3607 AA 3671 AA 
3609 AA 3675 AB 
3612 AB 3676 AA 
3615 BB 3679 AA 
3617 AB 3680 AB 
3618 AA 3684 AA 
3620 AA 3686 AA 
3632 AB 3687 AA 
3634 AB 3689 AB 
3637 AB 3690 AA 
3638 AA 3691 AB 
3640 AA 3692 AB 
3641 AB 3693 AB 
3645 AB 3694 AA 
3646 AA 3695 AA 
3647 AA 3697 AA 
3648 BB 3698 AB 
3649 AA 3699 AB 
3658 AA 3700 AB 
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West Coast Community Study Results 
Number C6 Genotype Number C6 Genotype 
3701 AB 3738 AB 
3703 AB 3739 AA 
3704 AA 3742 AA 
3708 AB 3743 AB 
3709 AB 3744 AA 
3710 AB 3745 AA 
3711 AA 3751 BB 
3712 AB 3752 BB 
3717 BB 3753 AB 
3718 AB 3756 AA 
3719 BB 3758 AB 
3721 AB 3759 AA 
3722 AB 3761 AA 
3723 AB 3766 AA 
3724 AB 3768 AB 
3725 AA 3769 AA 
3726 AB 3770 AB 
3728 AB 3772 BB 
3729 AA 3774 AB 
3730 AB 3775 AB 
373 1 AB 3777 AB 
3732 AA 3779 AB 
3734 AB 3780 AB 
3736 AA 3781 AB 
3737 AB 3783 AB 
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West Coast Communit:t Studr Results 
Number C6 Genot:tpe Number C6 Genot:tpe 
3786 BB 3822 AA 
3789 AB 3825 AA 
3790 BB 3826 AA 
3791 ABI 3827 AA 
3792 BB 3828 AB 
3793 AB 3829 AB 
3795 AB 3830 AA 
3796 AA 3832 AB 
3799 AB 3833 AB 
3801 AA 3834 AB 
3802 AB 3835 AA 
3804 AB 3836 AB 
3805 AB 3837 AB 
3806 AB 3838 AA 
3807 AB 3840 AB 
3808 AA 3841 BB 
3809 AB 3842 BB 
J812 BB 3843 AB 
3813 BB 3844 AB 
3816 AB 3847 AA 
3817 AB 3848 AA 
3818 AB 3849 AA 
3819 AB 3850 AB 
3820 AA 3851 AB 
3821 AA 3853 AB 
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West Coast Communit:t Stud:t Results 
Number C6 Genot:tpe Number C6 Genot:tpe 
3854 AB 3901 AB 
3856 BB 3902 AA 
3858 AA 3904 AB 
3859 AA 3906 AB 
3860 AA 3907 AB 
3861 AA 3908 AB 
3862 AA 3909 AB 
3863 AB 3911 BB 
3865 AA 3912 AB 
3868 AB 3913 AB 
3869 AB 3915 AA 
3871 AB 3916 AB 
3874 AA 3918 AA 
3875 BB 3920 AA 
3876 BB 3922 AB 
3878 AA 3923 AB 
3882 AB 3924 AB 
3883 AB 3927 AA 
3888 AA 3928 AA 
3889 AA 3931 AB 
3890 AA 3932 AA 
389 1 AA 3933 AB 
3892 AA 3934 AA 
3895 AA 3935 AA 
3900 AA 3937 AA 
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West Coast Communit:t: Stud:t: Results 
Number c6 Genotype Number C6 Genotype 
3938 AA 3987 AB 
3940 AA 3988 AB 
3943 AB 3990 AB 
3944 BB 3991 AB 
3945 AB 3992 AA 
3946 BB 3993 AB 
3947 BB 3994 AB 
3950 AA 3996 AB 
3959 AB 3997 AA 
3960 AB 3998 AA 
396 1 AB 3999 AA 
3965 AB 4000 AA 
3967 AA 4001 AB 
3969 AA 4002 BB 
3970 AA 4003 AA 
3971 AB 4079 BB 
3973 AB 4097 AB 
3974 AA 4135 BB 
3976 AA 4141 BB 
3977 BB 4142 AB 
3979 AB 4200 AA 
3982 AA 4240 AA 
3983 AA 4311 AB 
3985 AB 4440 BB 
3986 AB 4454 AA 
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West Coast Community Study Results 
Number C6 Genotype Number C6 Genotype 
4493 AB 5 157 AB 
4495 AB 5167 AB 
5004 BB 5170 AA 
5005 BB 5177 AA 
5506 AA 5182 AA 
5007 AB 51S7 AA 
5009 AB 51S9 AB 
5015 AB 5190 AB 
5017 AA 5191 AA 
5028 AA 5195 AA 
5029 BB 5198 AA 
5032 AA 5199 AA 
5034 AB 5201 AA 
5037 AB 5202 AA 
5039 AA 5204 AA 
5053 AB 5208 AA 
5063 AB 5212 AA 
5097 AB 5230 AB 
510S BB 5239 AA 
5112 AA 5246 BB 
5139 AA 5250 AB 
5140 AB 5257 AB 
5142 AB 5275 AA 
5148 AB 5280 AA 
5149 AA 5291 AA 
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West Coast Communit:t Stud:t Results 
Number C6 Genot:tpe Number C6 Cenotype 
5304 AB 5523 AA 
5305 AB 5524 AA 
5309 BB 5525 AB 
5320 AB 5526 AB 
5330 AB 6022 AB 
5405 AB 6212 AA 
5413 AA 6302 BB 
5415 AA 6305 AB 
5419 AA 6306 AB 
5438 AB 6308 BB 
5439 AA 6309 AB 
5450 AB 6500 AA 
5452 AA 6527 AB 
5457 AA 6563 AB 
5468 AA 6586 AB 
5469 AB 6587 AA 
5473 AA 6639 BB 
5515 BB 6640 BB 
5516 AA 6641 AB 
5517 BB 6649 BB 
5518 AB 6651 AB 
5519 AB 6652 AA 
5520 AB 6732 AA 
5521 AB 6733 AA 
5522 AB 6836 AB 
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West Coast Community Study Results 
Number C6 Genotype Number C6 Genotype 
7154 AA 
7156 AB 
7219 AB 
7220 AA 
7225 AB 
7244 AB 
7318 AB 
7319 AB 
8024 BB 
8026 BB 
8038 AA 
8212 AA 
9001 AB 
9002 BB 
9003 AB 
9004 AA 
9005 AB 
9006 AA 
9007 BB 
9008 AB 
9009 AB 
9010 BB 
9011 BB 
9996 AB 
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Newfoundland Fami l ies Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
BA 1001 BB BA 1133 AA 
BA 1004 AA BA 1135 AA 
SA 1005 AB BA 1138 BB 
SA 1019 BB BA 1139 AB 
SA 1021 BB BA 1141 AB 
SA 1025 AA SA 1142 AA 
SA 1030 BB SA 1154 AA 
BA 1037 AB BA 1162 AA 
BA 1040 AA SA 1165 AB 
SA 1043 AA SA 1167 AlA 
SA 1047 AA BA 1177 AA 
SA 1050 AA BA 1180 AA 
BA 1054 AA BA 1181 AA 
SA 1070 AA BA 1190 AA 
SA 1091 BB BA 1191 AA 
SA 1096 AA BA 1197 AA 
SA 1098 AB BA 1199 AB 
BA 1100 AB SA 1200 AA 
BA 1104 AB SA 1207 BB 
BA 1105 AB BA 1214 AA 
SA 1108 AB BA 1224 AA 
BA 1110 AB SA 1239 AB 
SA 1121 AA BA 1240 AA 
SA 1126 AA BA 1262 AA 
BA 1128 AB BA 1268 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Numher C6 Geno t ype 
BA 1269 AB BA 1415 AB 
BA 1302 AA BA 1416 AA 
BA 1304 AA BA 1417 BB 
BA 1307 AB BA 1418 AB 
BA 1308 AB BA 1420 AB 
BA 1309 AB BA 1421 AA 
BA 1327 AB BA 1422 AB 
BA 1335 BB BA 1423 AB 
BA 1336 AB BA 1424 AA 
BA 1338 AB BA 1425 AA 
BA 1358 AA BA 1426 AA 
BA 1362 AB BA 1427 AB 
BA 1366 AB BA 1428 BB 
BA 1370 AA BA 1429 AB 
BA 1373 AA BA 1430 AB 
BA 1387 AB BA 1431 AB 
BA 1389 AB BA 1432 AB 
BA 1390 AA BA 1433 AA 
BA 1392 AB BA 1434 AA 
BA 1393 AA BA 1435 AA 
BA 1396 AB BA 1437 BB 
BA 1408 AB BA 1439 AA 
BA 1410 AlA BA 1440 AA 
BA 1411 AB BA 1441 AA 
BA 1414 AA BA 1442 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Geno t ype Number C6 Genotype 
SA 1443 AA SS 1140 AA 
SA 1444 AB SS 1142 BB 
SA 1445 AA SS 1163 AB 
SA 1446 AA SS 1190 AB 
SA 1447 AB SS 1194 AA 
SA 1448 BB SS 1200 AA 
SA 1449 AB SS 1207 AB 
SA 1450 AB SS 123 1 AA 
SA 1451 BB SS 1235 BB 
SA 1452 AB SS 1271 AA 
SA 1453 AB SS 1273 AA 
SA 1454 AA SS 1321 AA 
SA 1455 AA sc 1018 AA 
SA 1456 AB SC 1045 AB 
SA 1457 AA SC 1050 AB 
SA 1458 AA SC 1051 AB 
SA 1459 AA SC 1122 AB 
SS 1023 AB SC 1163 AA 
SB 1045 AA SC 1185 AB 
SS 1086 BB BC 1186 AB 
SS 1097 BB SC 1187 AA 
SS 1115 AA BC 1189 AB 
BS 1116 AA BC 1190 AB 
SS 1135 AA SC 1191 AB 
SS 1138 AB SC 1209 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
BC 1210 AB FS 1000 AA 
BC 1211 AA FS 1001 BB 
BC 1212 AB FS 1002 A. 
BO 1003 AB FS 1003 A. 
BO 1040 AA FS 1004 AB 
BO 1056 AA FS 1006 AB 
BO 1061 AA FS 1007 AB 
BO 1062 AA FS 1008 AA 
BD 1063 AA FS 1012 BB 
BO 1078 AB FS 1014 B. 
BO 1080 BB FS 1019 A. 
BO 1126 AA FS 1020 A. 
BO 1144 AA FS 1025 A' 
BO 1175 AB FS 1026 AA 
BO 1229 A. FS 1029 BB 
BO 1230 AA FS 1032 AA 
BO 1231 A. FS 1033 AA 
BO 1232 AA FS 1034 AB 
BO 1233 A. FS 1035 AA 
BE 1002 AB FS 1036 AA 
BE 1009 A. FS 1037 AA 
BE 1032 AA FS 1038 A. 
BE 1096 AA FS 1039 A. 
BE 1114 A. FS 1040 A. 
BE 1115 AA FS 1041 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1042 AB FS 1102 AA 
FS 1049 BB FS 1109 AA 
FS 1050 AB FS 1113 AB 
FS 1051 BB FS 1114 AS 
FS 1052 AB FS 1116 AlA 
FS 1053 AS FS 1117 AS 
FS 1054 AB FS 1126 AA 
FS 1056 AA FS 1129 BB 
FS 1057 AS FS 1130 BB 
FS 1059 AA FS 1131 AB 
FS 1060 AA FS 1132 AA 
FS 1061 AA FS 1136 AA 
FS 1062 AA FS 1137 AB 
FS 1065 AA FS 1138 AA 
FS 1066 BB FS 1139 AS 
FS 1069 AA FS tl40 AA 
FS 1070 AA FS 1142 AA 
FS 1073 AA FS 1144 AA 
FS 1074 AB FS 1156 AB 
FS 1081 AA FS 1160 AA 
FS 1083 AB FS 1171 AB 
FS 1084 BB FS 1176 AA 
FS 1085 AB FS 1186 AA 
FS 1096 AA FS 1188 AB 
FS 1098 AS FS 1193 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1096 AA FS 1278 AA 
FS 1197 AB FS 1281 AA 
FS 1206 AB FS 1287 AA 
FS 1207 AB FS 1295 AB 
FS 1229 AB FS 1300 AA 
FS 1238 AB FS 1302 AA 
FS 1239 AA FS 1303 AA 
FS 1242 AA FS 1304 AB 
FS 1243 AA FS 1305 AB 
FS 1244 AB FS 1306 AB 
FS 1245 AB FS 1313 BB 
FS 1250 AA FS 1315 AA 
FS 1251 AA FS 1316 AA 
FS 1256 AB FS 1317 AA 
FS 1257 AB FS 1319 AB 
FS 1258 AA FS 1320 AB 
FS 1259 AB FS 1321 AB 
FS 1266 AA FS 1322 AA 
FS 1267 AB FS 1323 AB 
FS 1270 AA FS 1324 AB 
FS 1271 AA FS 1325 BB 
FS 1272 AA FS 1326 AA 
FS 1273 AA FS 1327 AA 
FS 1274 AA FS 1328 AA 
FS 1277 AA FS 1331 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1333 BB FS 1426 AA 
FS 1341 AA FS 1427 AB 
FS 1346 AA FS 1428 AA 
FS 1347 AA FS 1429 AB 
FS 1348 AB FS 1430 AB 
FS 1349 AA FS 1440 AA 
FS 1350 AA FS 1441 AA 
FS 1351 AA FS 1442 AA 
FS 1353 AB FS 1443 AB 
FS 1355 AB FS 1444 BB 
FS 1366 AA FS 1445 AB 
FS 1367 AA FS 1447 AB 
FS 1368 AA FS 1448 AA 
FS 1369 AA FS 1451 AB 
FS 1370 AA FS 1452 AA 
FS 1371 AB FS 1453 AA 
FS 1379 AB FS 1454 AA 
FS 1386 BB FS 1455 AB 
FS 1406 BB FS 1456 AB 
FS 1407 AB FS 1457 AA 
FS 1414 AB FS 1458 AA 
FS 1415 AB FS 1459 AA 
FS 1416 AA FS 1460 AB 
FS 1417 AA FS 1461 AA 
FS 1418 AA FS 1462 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1463 AA FS 1497 AA 
FS 1464 AB FS 1498 AA 
FS 1465 AA FS 1504 AA 
FS 1466 AB FS 1506 AA 
FS 1467 AA FS 1508 AB 
FS 1470 AB FS 1509 AA 
FS 1471 AA FS 1514 AA 
FS 1472 BB FS 1515 AA 
FS 1473 AB FS 1516 AB 
FS 1474 AA FS 1519 AA 
FS 1476 AA FS 1520 AB 
FS 1477 AA FS 1524 AB 
FS 1479 AA FS 1532 AA 
FS 1480 AA FS 1542 AA 
FS 1481 AA FS 1543 AB 
FS 1482 AA FS 1545 AA 
FS 1484 AB FS 1546 AA 
FS 1485 AA FS 1547 AB 
FS 1488 AA FS 1548 AB 
FS 1489 AA FS 1549 AB 
FS 1490 AA FS 1550 AB 
FS 1491 AA FS 1551 AB 
FS 1492 AA FS 1552 AA 
FS 1495 BB FS 1553 AA 
FS 1496 AA FS 1554 BB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1555 AA FS 1588 AB 
FS 1556 AB FS 1589 AA 
FS 1557 AA FS 1590 AA 
FS 1558 AB FS 1591 AA 
FS 1559 AB FS 1592 AA 
FS 1560 BB FS 1595 AB 
FS 1561 AA FS 1596 BB 
FS 1562 AA FS 1597 BB 
FS 1563 AA FS 1599 BB 
FS 1564 BB FS 1603 BB 
FS 1565 AA FS 1606 AA 
FS 1566 AA FS 1607 BB 
FS 1567 AA FS 1608 BB 
FS 1568 AB FS 1610 AA 
FS 1569 BB FS 1612 AA 
FS 1570 BB FS 1613 BB 
FS 1572 AB FS 1614 AB 
FS 1573 AB FS 1615 AA 
FS 1574 AB FS 1616 AA 
FS 1575 AB FS 1617 AA 
FS 1579 AA FS 1618 AB 
FS 1580 AB FS 1620 AA 
FS 1581 BB FS 1622 AA 
FS 1582 AA FS 1623 AA 
FS 1583 AA FS 1626 AB 
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Newfoundland Families Plus Random Individuals Results 
Number c6 Genotype Number C6 Genot:tpe 
FS 1627 AA FS 1659 AA 
FS 1628 AA FS 1660 AB 
FS 1629 AA FS 1661 AB 
FS 1630 AA FS 1662 AA 
FS 1631 AB FS 1663 AB 
FS 1632 AB FS 1664 BB 
FS 1635 AA FS 1665 AA 
FS 1636 AA FS 1666 AB 
FS 1637 AA FS 1667 AB 
FS 1638 AA FS 1669 AB 
FS 1639 BB FS 1670 AB 
FS 1640 AB FS 1673 AA 
FS 1642 AA FS 1674 BB 
FS 1643 AB FS 1676 BB 
FS 1644 AA FS 1681 AA 
FS 1645 BB FS 1686 AB 
FS 1646 BB FS 1689 AA 
FS 1647 AA FS 1690 AA 
FS 1651 AA FS 1691 AA 
FS 1652 AB FS 1692 AA 
FS 1653 AB FS 1693 AA 
FS 1654 AA FS 1694 AA 
FS 1655 AB FS 1695 AA 
FS 1656 AA FS 1696 AA 
FS 1657 AA FS 1697 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 GenotZ:Ee 
FS 1698 AA FS 1766 AB 
FS 1699 BB FS 1767 AA 
FS 1700 AA FS 1772 AA 
FS 1704 BB FS 1776 AA 
FS 1705 All FS 1779 AA 
FS 1706 BB FS 1780 AA 
FS 1719 AA FS 1781 AB 
FS 1720 BB FS 1782 AB 
FS 1723 AA FS 1784 AA 
FS 1727 AA FS 1786 AA 
FS 1728 AA FS 1787 AA 
FS 1733 AA FS 1788 AA 
FS 1734 AB FS 1792 AB 
FS 1739 AA FS 1793 AB 
FS 1742 AA FS 1794 All 
FS 1745 AB FS 1795 AA 
FS 1746 AB FS 1796 AA 
FS 1748 AA FS 1797 All 
FS 1749 BB FS 1798 AA 
FS 1758 AB FS 1799 AA 
FS 1761 AB FS 1800 AA 
FS 1762 AA FS 1801 AA 
FS 1763 AB FS 1802 AA 
FS 1764 AA FS 1806 AB 
FS 1765 AB FS 1807 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 1808 AB FS 1842 AA 
FS 1809 AB FS 1843 AA 
FS 1811 AB FS 1844 AA 
FS 1812 AB FS 1845 AA 
FS 1814 AA FS 1846 AB 
FS 1815 AA FS 1847 AB 
FS 1816 AA FS 1848 AB 
FS 1817 AA FS 1849 BB 
FS 1819 AB FS 1850 AB 
FS 1820 AA FS 1851 AB 
FS 1821 AB FS 1858 AA 
FS 1822 BB FS 1860 AA 
FS 1823 AB FS 1863 BB 
FS 1824 AA FS 1864 AB 
FS 1825 AB FS 1865 AB 
FS 1826 AB FS 1866 AB 
FS 1827 BB FS 1871 BB 
FS 1828 BB FS 1872 BB 
FS 1829 AB FS 1874 AA 
FS 1830 BB FS 1881 AA 
FS 1834 AB FS 1882 AA 
FS 1835 AB FS 1885 BB 
FS 1836 AB FS 1886 AB 
FS 1837 AB FS 1887 AB 
FS 1839 AA FS 1889 BB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genoti:l~e 
FS 1891 AB FS 1966 AA 
FS 1892 AB FS 1967 AA 
FS 1893 AA FS 1968 AA 
FS 1894 AA FS 1969 AA 
FS 1897 AB FS 1970 AA 
FS 1899 BB FS 1971 AA 
FS 1911 AB FS 1973 AB 
FS 1915 AA FS 1974 AB 
FS 1916 AB FS 1975 BB 
FS 1917 AB FS 1975 BB 
FS 1923 AA FS 1976 BB 
FS 1929 AA FS 1981 AA 
FS 1930 AB FS 1982 AB 
FS 1931 AB FS 1983 AB 
FS 1932 AB FS 1984 AA 
FS 1933 BB FS 1985 AA 
FS 1934 AB FS 1986 BB 
FS 1935 AB FS 1988 AB 
FS 1936 BB FS 1989 AA 
FS 1941 AA FS 1992 AA 
FS 1942 AA FS 1993 AA 
FS 1952 AB FS 1995 AA 
FS 1953 AB FS 1996 AB 
FS 1954 AB FS 1997 AA 
FS 1955 AB FS 1998 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotrpe 
FS 1999 AA FS 2050 AA 
FS 2000 AB FS 2051 AA 
FS 2003 AA FS 2052 AA 
FS 2004 BB FS 2053 AB 
FS 2005 AB FS 2054 AA 
rs 2011 AA FS 2055 AA 
FS 2012 AB FS 2056 AA 
FS 2013 BB FS 2057 AA 
FS 2014 AA FS 2061 AA 
FS 2015 AA FS 2062 AA 
FS 2017 AB FS 2063 AA 
FS 2018 AA FS 2064 AA 
FS 2019 AB FS 2065 BB 
FS 2020 AB FS 2066 AB 
FS 2029 AA FS 2067 BB 
FS 2030 AB FS 2069 AB 
FS 2033 AA FS 2072 AB 
FS 2035 AA FS 2073 AA 
FS 2036 AA FS 2074 AA 
FS 2039 AB FS 2075 AB 
FS 2040 AA FS 2076 AB 
FS 2041 AA FS 2077 AB 
FS 2042 AB FS 2078 AB 
FS 2044 BB FS 2081 BB 
FS 2048 AA FS 2088 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2089 AA FS 2132 BB 
FS 2090 ABI FS 2133 BB 
FS 2091 AA FS 3134 BB 
FS 2092 AA FS 3135 BB 
FS 2098 AA FS 2136 BB 
FS 2099 AB FS 2137 BB 
FS 2100 AA FS 2139 AB 
FS 2102 AA FS 2140 AB 
FS 2106 BB FS 2141 AB 
FS 2107 AB FS 2156 AB 
FS 2108 BB FS 2157 AB 
FS 2110 AB FS 2158 AB 
FS 21 11 AB FS 2159 AA 
FS 2114 AA FS 2160 AA 
FS 2115 AB FS 216 1 BB 
FS 2116 AA FS 2162 AA 
FS 2118 AA FS 2163 AA 
FS 2119 BB FS 2168 AA 
FS 2120 AA FS 2169 AA 
FS 2121 AA FS 2170 AB 
FS 2122 AA FS 2171 AA 
FS 2123 Al B FS 2172 AA 
FS 2125 AA FS 2173 AB 
FS 2126 AA FS 2174 AB 
FS 213 1 BB FS 2175 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genot:ipe 
FS 2176 AA FS 2238 AB 
FS 2179 BB FS 2239 AA 
FS 2183 AA FS 2240 AA 
FS 2189 BB FS 2243 AA 
FS 2190 AA FS 2244 AA 
FS 2191 AA FS 2245 AB 
FS 2192 AB FS 2246 AB 
FS 2193 AA FS 2247 AlA 
FS 2194 AA FS 2248 AA 
FS 2195 BB FS 2249 AB 
FS 2206 BB FS 2250 AA 
FS 2207 AA FS 2251 AlA 
FS 2208 ABl FS 2252 AA 
FS 2219 AB FS 2254 AB 
FS 2222 AA FS 2256 AB 
FS 2225 AB FS 2257 AB 
FS 2226 AB FS 2258 AA 
FS 2227 BB FS 2259 AB 
FS 2228 AA FS 2260 AA 
FS 2232 AA FS 2261 AA 
FS 2233 BB FS 2262 AA 
FS 2234 AA FS 2266 AA 
FS 2235 BB FS 2272 AA 
FS 2236 AA FS 2277 AA 
FS 2237 AA FS 2285 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2286 AA FS 2319 AB 
FS 2287 AB FS 2320 AA 
FS 2288 AlA FS 232 1 AA 
FS 2289 AlA FS 2322 AA 
FS 2295 AA FS 2325 AB 
FS 2297 AB FS 2327 AA 
FS 2298 AA FS 2335 AA 
FS 2299 AA FS 2336 AA 
FS 2300 AA FS 2337 AB 
FS 2301 AB FS 2338 AA 
FS 2302 AA FS 2339 AA 
FS 2304 AB FS 2340 AB 
FS 2305 AA FS 2348 AB 
FS 2306 AA FS 2350 AA 
FS 2307 AA FS 2353 AA 
FS 2308 AA FS 2357 AA 
FS 2309 AA FS 2359 AA 
FS 23 10 AA FS 2360 AA 
FS 23 11 AB FS 2361 AA 
FS 2312 Al A FS 2362 AA 
FS 2313 AA FS 2364 AA 
FS 23 14 AA FS 2365 AA 
FS 2316 AA FS 2366 AA 
FS 2317 AB FS 2368 AB 
FS 23 18 AA FS 2369 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2370 AA FS 2402 All 
FS 2371 AA FS 2403 AA 
FS 2372 AA FS 2404 AA 
FS 2373 AA FS 2405 AB 
FS 2374 AA FS 2406 AA 
FS 2375 AA FS 2407 AA 
FS 2376 AA FS 2408 AA 
FS 2377 AA FS 2409 BB 
FS 2379 AA FS 2410 BB 
FS 2384 AA FS 2411 BB 
FS 2385 AB FS 2414 BB 
FS 2386 AA FS 2415 All 
FS 2387 AB FS 2417 BB 
FS 2388 All FS 2418 AB 
FS 2389 AA FS 2419 BB 
FS 2390 All FS 2420 BB 
FS 2391 AB FS 2421 AB 
FS 2392 AA FS 2422 AA 
FS 2393 AA FS 2423 AB 
FS 2396 AA FS 2424 BB 
FS 2397 AB FS 2425 AB 
FS 2398 AB FS 2427 AA 
FS 2399 AA FS 2428 AA 
FS 2400 AB FS 2431 AA 
FS 2401 AA FS 2432 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2433 AA FS 2503 BB 
FS 2435 AB FS 2504 AA 
FS 2436 AA FS 2508 AA 
FS 2441 AA FS 2513 AA 
FS 2443 AB FS 2514 AA 
FS 2445 AA FS 2515 AA 
FS 2446 AA FS 2516 AA 
FS 2447 AA FS 2518 AA 
FS 2448 BB FS 2520 AB 
FS 2449 AA FS 2521 AB 
FS 2450 BB FS 2522 AB 
FS 2455 BB FS 2523 AB 
FS 2456 BB FS 2534 Al A 
FS 2464 AB FS 2535 AA 
FS 2465 AA FS 2536 AlA 
FS 2476 AB FS 2541 AB 
FS 2477 AA FS 2542 AB 
FS 2478 BB FS 2548 AB 
FS 2486 BB FS 2554 AB 
FS 2487 AB FS 2559 AB 
FS 2495 AA FS 2560 AB 
FS 2499 BB FS 2561 AB 
FS 2500 BB FS 2562 AA 
FS 2501 AB FS 2563 AB 
FS 2502 AA FS 2564 AA 
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Newfoundland Families Plus Random Individuals Results 
~ C6 Genotype Number C6 Genot:tpe 
FS 2565 AB FS 2622 AA 
FS 2566 AA FS 2623 AB 
FS 2567 AA FS 2624 BB 
FS 2571 AA FS 2625 AS 
FS 2573 AS FS 2628 AA 
FS 2574 AA FS 2632 AS 
FS 2575 AA FS 2633 BB 
FS 2585 AS FS 2634 AS 
FS 2587 AA FS 2635 BB 
FS 2588 BB FS 2639 AS 
FS 2593 AS FS 2640 BB 
FS 2594 AA FS 2641 AB 
FS 2595 BB FS 2642 AS 
FS 2598 AA FS 2643 BB 
FS 2600 AB FS 2644 AS 
FS 2603 AA FS 2646 AS 
FS 2613 AS FS 2647 AS 
FS 2614 AS FS 2648 BB 
FS 2615 AA FS 2649 AS 
FS 2616 AA FS 2650 AS 
FS 2617 AA FS 2651 AA 
FS 2618 AA FS 2664 AS 
FS 2619 AA FS 2665 AA 
FS 2620 AA FS 2666 AA 
FS 2621 AA FS 2667 AA 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2679 AA FS 2727 AA 
FS 2680 AS FS 2732 AA 
FS 2681 AB FS 2748 AB 
FS 2686 AA FS 2749 AA 
FS 2687 AA FS 2750 ABI 
FS 2691 AS FS 2751 AA 
FS 2692 AS FS 2752 ASI 
FS 2694 BB FS 2753 ASI 
FS 2698 AB FS 2756 AA 
FS 2704 AA FS 2770 BB 
FS 2705 AA FS 2771 AS 
FS 2706 AA FS 2772 AA 
FS 2707 AA FS 2773 AB 
FS 2708 AA FS 2783 AA 
FS 2709 AS FS 2784 AA 
FS 2710 AA FS 2785 AA 
FS 2711 AB FS 2788 AB 
FS 2712 AB FS 279 1 AA 
FS 2713 AA FS 2792 AA 
FS 2715 AS FS 2793 AA 
FS 2716 AA FS 2794 AA 
FS 2717 AB FS 2795 AA 
FS 2718 AA FS 2796 AA 
FS 2723 AA FS 2797 AB 
FS 2724 AA FS 2798 AS 
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Newfoundland Families Plus Random Individuals Re s ults 
Number C6 Genotype Number C6 GenotHe 
FS 2799 AA FS 2842 AA 
FS 2800 BB FS 2843 AA 
FS 2801 AA FS 2844 AA 
FS 2803 AA FS 2848 BB 
FS 2804 AA FS 2855 AA 
FS 2805 BB FS 2856 AA 
FS 2806 AA FS 2857 AA 
FS 2807 BB FS 2859 AB 
FS 2808 AB FS 2860 AA 
FS 2809 AA FS 2861 AA 
FS 2810 AB FS 2862 AA 
FS 2811 AA FS 2863 AA 
FS 2812 AB FS 2864 AA 
FS 2813 BB FS 2865 AA 
FS 2830 AA FS 2866 AA 
FS 283 1 AA FS 2867 AB 
FS 2832 AB FS 2868 AB 
FS 2833 AB FS 2869 AB 
FS 2834 AB FS 2870 AA 
FS 2835 AA FS 2872 AA 
FS 2836 BB FS 2873 AA 
FS 2837 BB FS 2874 AA 
FS 2838 AB FS 2875 AB 
FS 2839 AB FS 2876 AB 
FS 284 1 AB FS 2877 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 Genotype Number C6 Genotype 
FS 2878 AA FS 2921 BB 
FS 2879 AB FS 2923 AA 
FS 2880 AB FS 2924 AA 
FS 2881 AA FS 2925 AA 
FS 2882 AA FS 2926 AA 
FS 2883 AB FS 2929 AB 
FS 2884 AA FS 2930 AB 
FS 2889 AA FS 2933 AA 
FS 2890 BB FS 2934 AA 
FS 2891 AB FS 2935 AA 
FS 2892 AA FS 2936 AB 
FS 2893 AB FS 2937 AA 
FS 2894 AA FS 2948 AA 
FS 2895 AA FS 2949 AB 
FS 2897 AA FS 2952 AA 
FS 2902 AB FS 2953 AA 
FS 2903 AB FS 2954 AB 
FS 2904 AA FS 2955 AB 
FS 2905 AA FS 2956 AB 
FS 2906 AA FS 2957 AB 
FS 2907 BB FS 2958 AA 
FS 2911 BB FS 2959 AA 
FS 2912 AA FS 2960 AA 
FS 2913 BB FS 2962 AA 
FS 2920 AB FS 2963 AB 
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Newfoundland Families Plus Random Individuals Results 
Number C6 GenotYEe Number c6 GenotYEe 
FS 2964 AB FS 3001 AB 
FS 2965 AA FS 3106 AA 
FS 2966 AA 
FS 2967 AA 
FS 2968 AA 
FS 2969 AA 
FS 2970 AA 
FS 2971 AA 
FS 2972 AS 
FS 2973 AA 
FS 2974 AB 
FS 2975 AA 
FS 2976 SS 
FS 2978 AB 
FS 2984 AA 
FS 2986 AA 
FS 2987 AA 
FS 2988 AA 
FS 2989 AA 
FS 2992 AB 
FS 2993 AS 
FS 2994 AB 
FS 2997 AA 
FS 2998 AA 
FS 2999 AA 
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Labrador Mlotonic D:z:stro(l:h:z: Familr Results 
Number C6 Genotr(l:e Number C6 Genot:z:(l:e 
UOO AB U27 AA 
LI0l AB L128 AA 
LI02 AB L129 AA 
LI03 AS L130 AA 
L104 AS L131 AA 
LIOS AS L132 AA 
LI06 AS L133 AA 
LI07 AS L134 AA 
LI08 AS L135 AA 
Lll0 AA LI36 AA 
Ll11 AA L137 AA 
L112 AB L138 AA 
Ll13 AA L139 AA 
L114 AS Ll40 AA 
L115 AS L141 AA 
L1l6 AB L142 AA 
L1l7 AA L143 AA 
L118 AA L145 AA 
L119 AA L146 AA 
L120 AA L147 AS 
Ll21 AA L148 AA 
L122 AA L149 AA 
L123 AS L150 AA 
L125 AA L151 AB 
L126 AA L152 AS 
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Labrador M;i0tonic D;istroEh;i Famill Results 
Number c6 Genot;ipe Number C6 GenotlEe 
L155 AB L181 AA 
L156 AA L182 AA 
L157 AB Ll84 AA 
Ll58 AA LI85 AB 
L159 AB Ll86 AA 
Ll60 AB Ll87 AA 
Ll61 AB L188 AA 
L162 AA L190 AA 
Ll63 AA L191 AA 
L164 AA LI92 AA 
L165 AB L193 AA 
L166 AA L194 AA 
Ll68 AA Ll95 AB 
Ll69 AA L196 AB 
Ll70 AA L197 AA 
Ll7l AA Ll9.8 AA 
Ll72 AA L199 BB 
LI73 AA L200 AB 
L174 AA L201 AB 
L175 AA L203 AA 
L176 AA L204 AA 
LI77 AA L205 AB 
LI78 AA L207 AB 
L179 AA L209 AB 
L180 AA L210 AB 
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Labrador Myotonic Dystrophy Family Results 
Numbe r C6 Cenotype Number C6 Genotype 
L214 AA 
L215 AB 
L219 AA 
L223 AA 
L226 AA 
L227 AB 
L23 1 AA 
L241 AB 
L243 AB 
L246 AA 






